Oral Cancer in Tobacco and Betel Nut Chewers of Northern India: Correlation with Induced Protein Expression by Gatoo, Manzoor Ahmad
ORAL CANCER IN TOBACCO AND BETEL NUT CHEWERS 
OF NORTHERN INDIA: CORRELATION WITH 
INDUCED PROTEIN EXPRESSION 
L ^ 
ABSTRACT 
THESIS SUBMITTED FOR THE DEGREE OF 
Doctor of Philosophy 
„ j i f ' 
BIOCHEMISTRY 
M A N Z O O R A H M A D G A T O O 
p i^^^ DEPARTMENT OF BIOCHEMISTRY 
FACULTY OF MEDIC INE 
JAWAHARLAL NEHRU MEDICAL COLLEGE 
ALIGAHH M U S L I M UNIVERSITY 
AL IGARH ( INDIA) 
2008 
Fed in Conipuief A \^ 
i^  
^ ^ ^ u n s i ^ 
.^ r-^  
,er( Of^' 'boy )'<)| •• 
< ^ ^ 
vt? 
. • TT-1 ri -rT.' 
ABSTRACT 
Cancer is one of the most dreaded diseases of mankind that causes alarming mortality and 
morbidity in humans. It has long been evident that cancer has a multi-factorial 
etiology and is a multi-stepped process involving initiation, promotion and tumor 
progression. Chemical carcinogens, physical agents, ionizing radiation, viruses and 
other agents have all been implicated, and clearly host factors are also involved, 
mainly via an immunological and/or genetic basis. Cancer-predisposing genes may 
act not only via immune surveillance systems affecting the host's ability to 
recognize and eliminate incipient tumors, but also may affect the ability to repair 
damage to DNA or might affect the rate of metabolism of pre-carcinogens or 
carcinogens. 
Oral cancer is sixth most common cancer worldwide and third most common cancer 
in developing countries accounting for about up to 40% of all cancers. Incidence of 
oral cancer is increasing day by day due to more intake of various forms of tobacco 
and alcohol drinking, which are considered to be the two most important etiological 
factors in the development of oral cancer. It is estimated that 75-90% of all head and 
neck cancers are caused due to the tobacco use and tobacco users are between 20-40 
times more likely to develop head and neck cancer than non consumers, depending 
upon the amount of use as well as the age, sex and race of the user. Tobacco may be 
taken in various ways like smoking, and chewing. The most common form of 
tobacco chewing in India is betel quid. The 'quid' for chewing consists of areca nut 
and pieces of unripe betel fruit or areca nut wrapped in a piece of betel leaf together 
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with white or red lime. Betel quid chewing has'a strong association with oral cancer 
which arises predominantly from surface epithelium with evolution from early 
premalignant lesions. Oral SCC arise as a consequence of multiple molecular events 
induced by the effects of various carcinogens from habits such as areca nut and 
betel quid chewing, influenced by environmental factors, possibly viruses in some 
instances, against a background of inheritable resistance or susceptibility. An 
individual difference in the susceptibility to chemical carcinogens is one of the most 
important factors in the estimate of risk of human cancer as some patients appear 
susceptible because of inherited trait(s) in their ability or inability to metabolize 
carcinogens or pro-carcinogens, possibly along with an impaired ability to repair 
DNA damage. Oral carcinogenesis is a multi step process in which 6-10 genetic 
events lead to the disruption of the normal regulatory pathways that control basic 
cellular functions. In recent years, several alterations in the expression of tumor 
suppressor genes and oncogenes in the development of Oral Squamous Cell 
Carcinoma (OSCC) have been described. Keeping in view above facts, the present 
study was done to investigate the expression of p53 (product of tumor suppressor 
gene) and cyclin Dl (product of cell cycle regulator gene) as well as to the 
determine the frequency of polymorphism in DNA repair enzymes hOGGl, XRCCI 
and }ienobiotic metabolizing enzyme CYP2E1 in oral carcinoma patients with 
tobacco and betelquid chewing habit. 
The present study comprised of 250 human subjects with 100 oral cancer patients 
and 150 controls. Biopsy specimens were taken from 60 patients and 10 controls for 
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p53 and Cyclin Dl expression studies. Blood samples were collected from all the 
subjects for gene polymorphism studies. Immunohistochemistry was done to study 
the protein expression studies. For gene polymorphism studies, DNA was isolated 
from blood samples and quantified by agarose gel electrophoresis. Genotyping of DNA 
repair genes (hOGGI Ser^ ^^ Cys and XRCCI Arg^*°His) and xenobiotic metabolizing gene 
(CYP2E1 Rsal and Dral sites) was performed using PCR-RFLP technique. For statistical 
analysis, computer programme SPSS (version 13) was used. 
In the present study, out of the total 100 patients studied, 75 patients (75%) were 
males and majority of patients were in 50-75 age group and complained of 
dysphagia.The most common site of incidence of oral cancer in tobacco and betel 
quid chewers was buccal mucosa. 
It was found that there was no p53 or Cyclin Dl expression in normal tissues while 
in oral SCC patients with tobacco and betel quid chewing habit, the percentage of 
positive cases as well as p53 or Cyclin Dl positivity showed an increase with 
increasing grade of SCC. The expression of p53 was significantly associated with 
histological grade in oral cancer in tobacco and betel quid chewers while no such 
association was found between Cyclin Dl expression and histological grade. 
Statistically significant difference was observed in Cyclin Dl positivity between 
well differentiated SCC and moderately differentiated SCC as well as between well 
differentiated SCC and poorly differentiated SCC. Similarly significant difference 
in Cyclin Dl positivity was observed between moderately differentiated SCC and 
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poorly differentiated SCC but in case of p53 expression, statistically significant 
difference in p53 positivity was observed only on comparing well differentiated 
SCC with poorly differentiated SCC. 
Expression of oncoproteins was not similar in different sites of oral cavity. p53 
expression was more frequently seen in gingivia, floor of mouth, tongue, and buccal 
mucosa while Cyclin Dl expression was more frequently seen in hard palate, buccal 
mucosa and lip. 
The polymorphism studies of DNA repair genes (XRCCI Arg^^^His and hOGGI 
Ser^ ^^ Cys) and xenobiotic metabolizing gene (CYP2E1 Dral and Rsal sites) revealed that 
these polymorphisms were significantly associated with risk of oral cancer in tobacco and 
betel quid chewers. The individuals with variant XRCCI Arg^ °^His and hOGGI Ser^ ^^ Cys 
genotypes were at increased risk of oral cancer as compared to individuals having wild 
type homozygous genotypes. Thus XRCCI Arg^ °^His and hOGGI Ser^ ^^ Cys 
polymorphisms lower DNA repair ability in tobacco and betel quid chewers which results 
in increase in risk of oral cancer in this epidemiologically distinct population. The 
individuals with the variant genotype of xenobiotic metabolizing gene (CYP2E1 Rsal 
and Dral sites) were at increased risk of oral cancer as compared to individuals having 
wild type genotypes thus supporting the hypothesis that environmental exposure to the 
carcinogens plays an important role in the etiology of oral cancer. 
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In conclusion, it was found that there was over expression of tumor suppressor gene 
product, p53 and cell cycle regulator gene product, cyclin Dl in oral SCC patients from 
northern India with tobacco and betel quid chewing habit. It was also observed that 
XRCCI Arg^*°His, hOGGI Ser ^^ ^Cys, CYP2E1 Oral and CYP2E1 Rsal polymorphisms 
were closely associated with high risk of oral cancer in this epidemiologically distinct 
population. 
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CHAPTER 1 INTRODUCTION 
About thirty three years ago, US President Richard Nixon declared the "war on 
cancer" in 1974 with the hope and anticipation that death from cancer might be 
greatly reduced by the end of last century. In spite of advances in cancer research 
and treatment, it still remained a major global health issue. In 2000, cancer 
accounted for over 7 million deaths and there were more than 10 million new 
cases worldwide by the end of new millennium (Shibuya et ai, 2002). According 
to report of American Cancer Society on cancer statistics, cancers of the lung, 
prostrate, colon and rectum in men and cancers of the lung, breast, colon and 
rectum in women continue to be the most common causes of cancer deaths 
(Jemal et al, 2002). These four types of cancer account for more than half of 
total cancer deaths among men and women. 
Carcinogenesis is a complex, multi-step process in which signal transduction 
pathways involved in various normal cellular physiology are quantitatively or 
qualitatively altered (Vogelstein and Kinzler, 1993). Under normal conditions, 
these tightly controlled excitatory or inhibitory pathways regulate cellular 
functions like cell division, differentiation and senescence. 
Although the cellular pathway of different types of cancers may be diverse, they 
contain the same fundamental elements. An extra cellular ligand, such as a 
growth factor binds to a cell surface receptor. The receptor-ligand complex 
generates excitatory or inhibitory signals, sent through intracellular and nuclear 
messengers that can either directly alter cell function or can stimulate the 
transcription of genes whose proteins effect change (Bishop, 1991). Cancer is the 
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result of accumulation of changes in the excitatory or inhibitory cellular 
pathways that can occur at any level of a given pathway. As the cell collects 
these alterations or mutations; it becomes functionally independent from the 
surrounding cells. The normal cellular functions tightly controlled by the 
stimulatory and inhibitory pathways are subverted in the tumor cell, allowing it 
to divide more rapidly, sequester blood vessels to feed that growth, delete or 
amplify signals to produce abnormal structural or functional changes, and invade 
normal tissue at local or distant sites (Weiner and Cance, 1994). 
It has long been evident that cancer has a multi-factorial etiology and is a multi-
stepped process involving initiation, promotion and tumor progression. Chemical 
carcinogens, physical agents, ionizing radiation, viruses and other agents have all 
been implicated, and clearly host factors are also involved, mainly via an 
immunological and/or genetic basis. Cancer-predisposing genes may not act only 
via immune surveillance systems affecting the host's ability to recognize and 
eliminate incipient tumors, but also may affect the ability to repair damage to 
DNA or might affect the rate of metabolism of pre-carcinogens or carcinogens. 
According to famous British pathologist, R. A. Wills (1960), tumor can be 
defined as, "An abnormal mass of tissue, the growth of which is in excess and 
uncoordinated with the normal tissue and persists in the same excessive manner, 
even after the cessation of the stimuli that evoked the change." The six major 
alterations in cell physiology that collectively dictate malignant growth 
(Hanahan and Weinberg, 2000) are:-
Self-Sufficient in growth signals 
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Insensitivity to growth inhibitor signals 
Evasion of apoptosis (programmed cell death) 
Limitless replicative potentials 
Sustained angiogenesis and adjoining tissue invasion 
Metastasis 
Each of these physiological changes acquired during tumor development 
represent the successful breaching of an anticancer defense mechanism. These 
six features are shared in common by most types of human and animal tumors. 
Cancer may be caused by a variety of causative factors, usually over a period of 
many years. Many specific causes of cancer are now known, the most important 
being difference in lifestyle, occupational exposure and exposure to oncogenic 
viruses, but a large proportion of global variation for human cancers remains still 
unexplained. The known risk factors for cancer can be broadly divided into 
'Environmental' and 'Host factors'. Environmental factors can be further 
subdivided into "chemical, physical and biological". 
In this era of modernization and technology, large numbers of chemicals enter 
into our environment through occupational exposure, automobile exhausts, 
pesticides, industrial wastes and contamination of food and water. These 
chemicals exist in the environment in a relatively stable condition until taken in 
by an exposed individual and activated. Thus, these chemicals appear to pose a 
great concern and threat to man. Polycyclic Aromatic Hydrocarbons (PAH), 
nitrosamines, mycotoxins, pesticides and metallic contaminants such as arsenic 
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and cadmium are some of xenobiotics that can enter in our food chain during 
processing, storage, preservation and cooking. According to International 
Agency for Research on Cancer (lARC), now there are about 88 chemicals, with 
sufficient evidences of carcinogenic potential in humans (lARC, 1994). Physical 
agents such as ultra-violet rays (UV) and the ionizing radiations (X-rays, 
gamma-rays) are known to be hazardous in nearly all tissues or organs of human 
or experimental animals depending upon the radiation dose and exposure 
schedule (lARC, 1992).The scenario is becoming alarming with the application 
of nuclear technology in science, medicine, and industries and expanding use of 
these radiations in diagnosis and therapy of the disease itself (Trichopoulos et 
al. 1996). 
Biological agents, such as retroviruses, bacteria and parasitic infections, the 
oncogenic viruses such as papillomas-viruses, feline-leukemia viruses and 
bovine -leukosis virus are linked with increased incidence of various types of 
neoplasia. The Epstein-Barr virus has shown to be implicated with the 
occurrence of Burkitt's lymphomas, Hodgkin and non -Hodgkin lymphoma and 
pharyngeal carcinoma (Cordova Perez et al, 2003; Young and Murray, 2003). 
Certain bacteria like Helicobacter pylori are also implicated in the development 
of cervical, esophageal, head, neck and stomach cancer (Peto, 2001). 
Various factors that can play crucial role in establishment of cancer are host 
(internal) factors comprised of hormonal disturbances, immune functions and 
inherited predisposition to certain cancers. The genetic manipulations such as 
activation of cellular proto-oncogenes and alterations in tumor suppressor genes 
aaaaaBaBSBaaBBBasBBaaaKSKaBSBiiBSBaaaaaBBBaBaaaBaaaa^ 
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also result in aberrant proliferation of cells (Ames et al, 1995; Peto et ai, 2001). 
Many cancer chemotherapeutic drugs, particularly vinca alkaloids, alkylating 
agents, immunosuppressive agents and certain cyclosporins are also reported to 
increase the cancer risk. (Ames et al, 1995; Trichopoulos et al, 1996; 
Chauvenet et al, 2003). 
Besides, the choice of lifestyle and habits such as tobacco, smoking and 
chewing, high alcohol intake, high fat diet and dietary habits, are also thought to 
initiate or promote various forms of cancers (lARC, 1993). About 40-60 percent 
of all cancers are related to our food choices and about one third of all cancer 
deaths may be related to what we eat. Besides diets high in fat, low in fiber, 
vitamins, fruits, vegetables, over weight and obesity, lack of physical activity etc 
have been associated with increased incidences of cancer (La Vechia et al, 
1993; Rajkumar et al, 2003). Thus most of the prevalent human cancers to a 
significant extent can be prevented and many could be avoided by a suitable 
choice of lifestyle, diet and environment. 
Carcinogenic risk from exposure to exogenous chemical carcinogens depend not 
only on the intrinsic nature and dose of each chemical, but also may depend on 
inter-individual variability in sensitivity to the carcinogens. An individual 
difference in the susceptibility to chemical carcinogens is one of the most 
important factors in the estimate of risk of human cancer (Clapper ML, 2000). 
Oral cancer is sixth most common cancer worldwide and third most common 
cancer in developing countries accounting for about up to 40% of all cancers 
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(Parkin SM et al, 1988). Oral cancer includes cancer of lip, tongue, buccal 
mucosa, vestibule, gingiva, palate and floor of mouth and tongue being most 
common site for both males and females (Johnson NW et al, 1993; Park BZ et 
al., 1998). Oral cancer incidence increases with age and its rate varies widely 
throughout the world. India and South East Asian countries have highest rate of 
incidence of oral cancer while developed countries have low incidence rate of 
oral cancer. Incidence of oral cancer is increasing day by day due to more intake 
of various forms of tobacco and alcohol, which are considered to be the two most 
important etiological factors in the development of oral cancer. It is estimated 
that 75-90% of all head and neck cancers are caused due to the use of tobacco 
which includes cigarettes, pipes, cigars and smokeless tobacco (chew, dip, snuff, 
betel quid and areca nut). Tobacco users are between 20-40 times more likely to 
develop head and neck cancer than non consumers, depending upon the amount 
of use as well as the age, sex and race of the user (La Vechia C et al., 1997; 
Cawson RA et al, 1996; Graham S et al, 1997). 
Tobacco smoke consists of more than thirty different carcinogenic compounds 
particularly nitrosamines and polycyclic aromatic hydrocarbons. Alcohol and 
tobacco act independently of one another to raise the relative risk of oral cancer 
(Elwood et al, 1984). In joint exposure risk, alcohol acts synergistically with 
tobacco (Notani et al, 1988; Sankaranarayanan et al, 1989, 1990). Oral cancer 
risk is related to these etiological factors by qualitative as well as quantitative 
point of view. It depends upon the duration of intake, age of onset, time since 
quitting, amount and type of tobacco and alcohol taken. Risk is also related to 
the demographic, cultural, socio- educational, occupational, dietary differences. 
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oral hygiene, compromised dentition and ionizing radiations (Notani 1988; 
Nandakumar et al, 1990; Hebert et al, 1993; Balaram et al, 2002). 
Tobacco may be taken in various ways like smoking and chewing. Tobacco may 
be smoked in the form of manufactured cigarettes or indigenous forms like Bedi, 
Chutta (Agra), Chilum, Hooka (hubble-bubble) and pipe etc. There is strong 
dose-response relationship between tobacco intake and incidence of oral cancer. 
The most common form of tobacco chewing in India and Taiwan is betel quid. 
The 'Quid' for chewing consists of areca nut and pieces of unripe betel fruit or 
areca nut wrapped in a piece of betel leaf together with white or red lime. Betel 
quid chewing has a strong association with oral cancer which arises 
predominantly from surface epithelium with evolution from early premalignant 
lesions. The preneoplastic lesion may exist for years before invasion, and may 
behave persistently and progressively after abstinenance from betel quid 
chewing. In Taiwan, there are about 2 million people who are suffering from the 
habit of betel quid chewing and approximately 80% of all oral cancer deaths are 
associated with this habit (Kuo et al, 1999). 
The consumption of alcohol is linked to development of cancer in upper 
acrodigestive tract particularly the oral cavity and oropharynx. The exact 
mechanism is unclear but it is thought to be that due to a combination of local 
toxic effects on the mucosa and systemic effects from the associated dietary 
deficiency, hepatic damage and possible alteration in the patient's immunity. 
Infection agents have also been implicated as possible causes of cancer in the 
oral cavity like Treponema Pallidum, Human Papilloma Virus and Candida 
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albicans (Crispian Scully 1993). So there may be multiple etiological factors 
which play significant role in the development of oral cancer. In 1944, Willis 
stated that when carcinogenic stimuli affect epithelial tissue, all the epithelium in 
that area is affected similarly, but not necessarily equally. A neoplasm, therefore, 
is more likely to develop in tissue in which the stimuli have been maximal; 
however, similar neoplastic change may occur at a later stage in adjacent tissue 
that was exposed to the same carcinogen. The mucosa of the upper aero digestive 
tract should, therefore, be regarded as a field of growth that is constantly being 
bathed by the carcinogens and therefore will potentially have numerous areas of 
malignant and early malignant change. Early symptoms of oral cancer include 
persistent mouth ulcers (frequently painless), warty lumps and nodules, white 
red, speckled or pigmented lesions, recent onset of difficulty with speaking or 
swallowing and enlarged neck nodes. Any new oral lesion that persists longer 
than 3 weeks should be referred for a specialist opinion and also 
histopathological examination. 
Incidences of oral cancer are very high in India and South East Asian countries 
in comparison to the western countries (lARC, 2002). Unlike in the west, most of 
the oral cancers seen in India, are preceded by distinct premalignant lesions such 
as leukoplakia and sub mucous fibrosis. The incidence of oral cancer is affected 
by age of the person, sex, site of cancer, religion, diet, tobacco and alcohol 
intake (Nandakumar et al, 1990; BaJaram et al, 2002). Incidence of oral cancer 
increases with age and shows steep rise in the age group of 60 to 64. Oral cancer 
is more frequent in males than females with gender ratio between 2:1 to 6:1. The 
most usual site of incidence of oral cancer is tongue followed by floor of mouth. 
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Risk of oral cancer increases with increased use of alcohol and tobacco in its 
various forms. The effect of these factors have been studied by various 
researchers (Znaor et al, 2003; Jayant K. et ai, 1987; Sankaranarayanan R. et 
al, 1990; Balaram P. et al, 2002 ). In this study, we analyzed the incidence of 
sex, age and site of cancer in oral cancer patients with tobacco and betel quid 
chewing habit in northern India. We also analyzed the relation of tobacco and 
betel quid chewing with oral cancer. 
Oral carcinogenesis is a multi step process in which 6-10 genetic events lead to 
the disruption of the normal regulatory pathways that control basic cellular 
functions (Vogelstein and Kinzler, 1993). In recent years, several alterations in 
the expression of tumor suppressor genes and oncogenes in the development of 
oral squamous cell carcinoma (OSCC) have been described (Williams HK et al, 
2000; Michalides. RJAM, 1999). Regular exposure of the oral cavity to betel 
quid and areca nut induces "field cancerization" involving initiation of different 
changes in the cellular DNA. Advances in the field of tumor suppressor genes 
and oncogenes have provided a tool to study the genetic changes occurring at 
different stages of carcinogenesis. In the present study, an attempt was made to 
investigate the expression of p53 and Cyclin Dl in tobacco and betel quid related 
oral SCC's in northern India. 
The ability to metabolize carcinogens or pro-carcinogens, repair DNA damage, 
and control cell signaling and the cell cycle are fundamental to homeostasis. 
OSCC, under appropriate exposure to areca nut and betel quid, arise if these 
mechanisms are defective. Oral SCC arise as a consequence of multiple 
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molecular events induced by the effect of various carcinogens from habits such 
as tobacco and betel quid chewing, influenced by environmental factors, possibly 
viruses in some instances, against a background of inheritable resistance or 
susceptibility. Consequent genetic damage may affect many chromosomes and 
genes, and it is the accumulation of these changes that may lead to carcinoma in 
some instances, sometimes via a clinically evident pre-malignant or potentially 
malignant lesion (Field, 1992; Yokes et al, 1993). Although lifestyle factors 
play an important role in etiology, some patients appear susceptible because of 
inherited trait(s) in their ability or inability to metabolize carcinogens or pro-
carcinogens, possibly along with an impaired ability to repair DNA damage. The 
characterization of genetic determinants for oral cancer susceptibility is 
important for understanding the disease pathogenesis and for defining preventive 
measures. There is growing evidence that a group of predisposing polymorphic 
genes exists, such as those involved in carcinogen metabolism, which may 
increase cancer incidence in certain environmentally exposed subjects, even 
when exposed only to low levels of carcinogens. Within preventive strategies, it 
is therefore necessary to identify these vulnerable members in our society, in 
particular those suffering from an unfavorable combination of high carcinogen 
exposure, cancer predisposing genes, and lack of protective (dietary) factors. 
Thus, molecular epidemiology faces the difficult task of analyzing carcinogen 
exposed individuals for a combination of "at risk" genotypes associated with 
higher cancer susceptibility. Rather than taking cancer as an end point, 
combinations of cancer predisposing genes can then be explored to better define 
gene environmental interactions and provide knowledge that should facilitate the 
identification of high risk subjects within carcinogen exposed population. Thus, 
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by identifying the "at risk" genotype combinations that may serve as markers, it 
is possible to identify susceptible consumers of tobacco and chewing products 
who are at risk for developing pre-cancerous lesions in a population based study. 
In view of the rapid upsurge in the incidence of oral precancerous lesions, in 
both genders and high risk of transition to malignancy, there is urgent need to 
determine the relationship between polymorphisms in cancer susceptibility genes 
and risk of developing tobacco related oral precancerous lesions and cancers. 
The study will also help in understanding the mechanism underlying 
pathogenesis of the disease and aid in identifying markers for predicting high 
risk population. 
An individual difference in the susceptibility to chemical carcinogens is one of 
the most important factors in estimate of risk of oral cancer. Most chemical 
carcinogens require metabolic activation by phase I enzymes (Cytochromes P-
450) and detoxification by conjugation via the various phase II enzymes 
(epoxide hydrolase, glutathione S-transferase, N-acetyl transferase, sulfur 
transferase etc) (Ernster et al, 1991). Thus, the coordinate expression and 
regulation of phase I and phase II drug metabolizing enzymes and their 
metabolic balance may be an important host factor in determining whether 
exposure to carcinogen results in cancer or not (Idle et al, 1991). At present, it is 
accepted that most of the carcinogens in our environment are activated mainly by 
restricted number of P-450 species, including CYPIAl, CYPIA2. CYP2E1 and 
CYP3A (Guengerich et al., 1991; Kawajiri et al, 1991).CYP2EI polymorphism. 
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has been associated with an increased risk for tobacco related diseases such as 
lung cancer. 
Various cellular metabolic processes result in the formation of hydroxyl radicals 
that can cause oxidative damage to DNA (Demple B et al, 1994). This damage 
often results in single base changes that can be reversed by Base Excision Repair 
(BER) mechanism (Lindahl T et al, 1999). hOGGI and XRCCI are two of 
enzymes participating in the BER pathway, DNA repair system involved in the 
repair of damage resultant from oxidative stress. The enzyme hOGGI can 
recognize and excise OH-8-Gua, the major form of oxidative DNA damage 
induced by reactive free radicals (Burner S.D et al, 2000). XRCCI complexes 
with DNA polymerase via the NH2 terminus domain and with DNA ligase 111 
via a blue ribbon commission on transportation (BRCT) domain to repair nicks 
or gaps left in the BER pathway (Nash R.A. et al, 1997). XRCCI has also been 
shown to be involved in the detection of single strand breaks between incision 
and ligation, and effect that likely occurs via poly (ADP-ribose) polymerase 
dependent and poly (ADP-ribose) polymerase-independent mechanisms (Masson 
M et al, 1998). Genetic polymorphisms of DNA repair genes have been reported 
to determine susceptibility to several cancers including lung, esophageal, bladder 
and nonmelanoma skin cancers (Perera FP. 1996). The aim of present study is to 
determine the frequency of polymorphism in DNA repair enzymes hOGGl, 
XRCCI and xenobiotic metabolizing enzyme CYP2E1 in relation to tobacco and 
betel quid chewing that may serve as markers to identify individuals susceptible 
to develop oral cancer. 
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CHAPTER 2 LITERATURE REVIEW 
Definition 
The term "oral" includes the lips and all intra-oral sites corresponding to the ICD9 codes; 
140 (lip), 141 (tongue), 143 (gum), 144 (floor of mouth) and 145 (other non-specific 
sites), but excludes sites 142 (major salivary glands), 146 (oropharynx), 147 
(nasopharynx), 148 (hypopharynx) and 149 (ill defined oral/oropharynx) (Johnson NW et 
al, 1993). Approximately 90% of oral cancers are primary squamous cell carcinomas 
arising from the lining mucosa of the mouth, most commonly the tongue and the floor of 
the mouth (Park BZe/o/., 1998; Johnson NWeM/., 1993). 
Histopathology of Oral Cancer 
The development of oral cancer seems to begin in many cases with exposure of the 
mucosal surfaces of the upper aerodigestive tract to topical carcinogens, predominantly 
alcohol and tobacco (Blot WJ et al, 1988; Nam J et al. 1992; Yokes EE et al, 1993; 
Million RP et al, 1993). In some persons upon exposure to these carcinogens or co-
carcinogens, there develop premalignant and malignant lesions in a multi-step process 
within the mucosa (Lippman SM et al, 1990; Brachman DG et al, 1994). However, oral 
cancers occur in some patients with no history of tobacco or alcohol usage and no other 
apparent risk factors. Additionally, it is not clear whether all of the tumors have an 
apparent "precancerous" state. 
The earliest detectable morphologic changes are the appearance of the "premalignant" 
lesions of leukoplakia and erythroplakia (Waldron CA et al, 1975; Skhlar G et al, 1986; 
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Hansen LS et al, 1995). Leukoplakia is a white plaque that cannot be removed by gentle 
scraping and for which no other etiology can be identified. Microscopically, leukoplakias 
exhibit hyperplasia of keratinocytes, as represented by hyperorthokeratosis, 
hyperparakeratosis, and/ or acanthosis. 
The term dysplasia is reserved for lesions showing combinations and degrees of cytologic 
atypia (e.g., hyperchromatism, increased nuclear size, pleomorphism, dyskeratosis, and 
increased or abnormal mitotic figures) (Skhlar et al, 1986; Yokes et al, 1993). Atypia 
confined to basilar and parabasilar keratinocytes constitutes mild dysplasia, whereas 
atypia extending into the midspinous layers is termed moderate dysplasia. When cellular 
atypia extends to the surface layer, the terms severe dysplaisa and carcinoma in situ 
(complete top-to-bottom cytological atypia) are applied. Architectural changes are also a 
feature of dysplasia, the most significant being a bulbous or teardrop shape of rete ridges. 
For oral mucosa in general, up to 20% of clinically defined leukoplakias that are biopsied 
may exhibit dysplasia while lesions located in the floor of the mouth approach a 40% 
prevalence of dysplastic change (Waldron CA et al, 1975). Dysplastic leukplakias have a 
high propensity to progress to invasive squamous cell carcinoma. However, leukoplakias 
without evidence of dysplastic changes may progress to dysplasia and subsequently to 
carcinoma, whereas many leukoplakias fail to undergo malignant transformation (Mincer 
HH, 1972; Silverman S Jr, 1984). 
Erythroplakia is a velvety red patch of oral mucosa that does not conform to other 
defined oral disease processes. There is a high prevalence of dysplastic changes among 
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these lesions, approaching 80-90%, and progression to invasive carcinoma is high (Shafer 
WG, 1975; Yokes EE et al, 1993; Million PP et al, 1993). Although dysplastic, the 
epithelium is usually atrophic, and submucosal vasodilation with inflammatory cell 
infiltration is a consistent finding. When erythroplakias coexist with white foci, they are 
termed speckled leukoplakias or erythroleukoplakias and such lesions exhibit 
hyperkeratosis in the white areas. 
Malignancies arising from the mucosa of the oral cavity are epithelial in origin and are, 
therefore, classified as squamous cell carcinomas more than 90% of the time (Zarbo RJ et 
al, 1988; Silverman S Jr et al, 1990). According to the degree of differentiation, three 
subtypes are defined: (1) well-differentiated squamous cell carcinoma showing more than 
75% keratinization; (2) moderately differentiated squamous cell carcinoma with 25%-
75% keratinization; and (3) poorly differentiated squamous cell carcinoma with less than 
25% keratinization (Million RP et al, 1993; Yokes EE et al, 1993). A clear relationship 
between histologic differentiation and clinical prognosis has not been established, 
although a lack of differentiation has been associated with more rapid growth and spread. 
The morphologic classification of squamous cell carcinoma by degree of differentiation 
is used in the description of the histopathologic specimen. 
There are histopathologic variants of squamous cell carcinoma, all of which are rare, that 
affect prognosis and the selection of therapeutic modalities. Spindle cell or sarcomatoid 
squamous cancers, occasionally found in the oral cavity, are most frequently encountered 
on the lip and in the larynx. Radiation therapy to a pre-existing conventional squamous 
CHAPTER 2: LITERATURE REVIEW 15 
cell carcinoma is a common antecedent event; however, spindle cell carcinomas my arise 
de novo (Ellis GL et al, 1980). Other rare variants of oral, head and neck carcinoma 
include psueudoglandular, basaloid, and small cell neuroendocrine carcinomas, the latter 
two being radiosensitive. Because these tumors share histopathologic features with other 
neoplasms (i.e., melanomas, neuroblastomas, lymphomas), the use of specific 
immunohistochemical markers is warranted. 
Verrucous histopathology patterns characterize a subset of oral epithelial tumors. 
Because there is evidence that these carcinomas evolve from leukoplakias that also 
exhibit a verrucoid architecture, they are termed proliferative verrucous leukoplakia 
(PVL) (Hansen S et al, 1995). Two specific forms of squamous cancers may arise from 
PVL lesions. The first, verrucous carcinoma is characterized by marked 
hyperparakeratosis, acanthosis, parakeratin crypts, and large "pushing" bulbous rete 
ridges, said to resemble "elephant's feet" (Blot WJ et al, 1988). It shoud be noted that 
verrucous carcinomas do not have dysplastic cytologic features and they do not 
metastasize. 
The second variant, also often preceded by PVL, is the papillary form of squamous cell 
carcinoma. Histologically, these lesions exhibit either an exophytic papillary pattern of 
growth or a verrucous inverting architecture (Crissman JD et al, 1988; Ishiyama A et al, 
1994). Both patterns harbor dysplastic cytologic changes while a small number (less than 
10%) have been shown to metastasize to regional nodes. 
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Staging of Intraoral Carcinoma 
Many types of clinical classifications for the primary growth in oral cavity have been 
advocated by various researchers viz. 
1. Paymaster's classification, 
2. T.N.M. Staging 
1. Paymaster's Classification: 
Paymaster in 1957 advised staging of the disease on the basis of extent of primary growth 
and size of metastasis in cervical nodes. He classified primary grovk^ h into 3 groups. 
Primary Growth 
1 P.A: Primary growth less than 11/2 cm in diameter strictly localised to the anatomical 
structure in which it is arising (Early and operable stage). 
2. P.B.: Primary growth less than 3cm in diameter strictly localised to the anatomical 
structure in which it is arising (Moderately advanced yet operable stage). 
3. P.C.: Primary growth less than 3 cm in diameter, disease extends to the adjacent 
structure (Advanced inoperable). 
The Size and Extent of Metastasis 
M; Metastasis 
1. M.A: Metastatic mass less than 1 "2 cm in diameter. Nodes mobile (Early and 
operable). 
2. M.B: metastatic mass less than 3 cm in diameter, glands moderately enlarged and not 
fixed (Moderately advanced yet operable). 
• B B B a a ^ B ^ 
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3. M.C: Metastatic mass more than 3 cm in diameter, metastatic nodes hard and fixed 
(Advanced Inoperable stage). 
Clinical Staging was done on these features into 3 groups-
Early, fit for Curative Surgery or Stage I 
Stage II : 
Stage III : 
P.A. +M.A 
P.B. +M .A I Radiotherapy 
P.A. +M.A 
P.A. + M.B 
P.B. + M.A 
P.B. + M.B 
Advanced but Operable 
P.A. +M.C 
P.B. + M.C 
P.C. + M.C 
P.C. + M.A 
P.C. + M.B 
Advanced Inoperable 
2. T.N.M. Classification (2002) 
This classification was given by the international union against cancer (UICC) in 2002 
and is based on assessment of three components as follows: 
(1) 'T' denotes Primary Tumor and T1-T4 relates to the extent of tumor itself 
(2) 'N' denotes Lymph Node Metastasis and is described by No- N3 
(3) 'M' denotes Distant Metastasis and is described Mo-Mi 
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Primary Tumor 'T' is classified into following stages-
TX: Primary tumor cannot be assessed 
TO: Noevidenceof primary tumor 
Tis: Carcinoma in situ 
T1: Tumor 2 cm or less in greatest dimension 
T2: Tumor more than 2 cm but not more than 4 cm in greatest dimension. 
T3: Tumour measuring more than 4 cm in largest dimension 
T4 (Lip): Tumor invades through cortical bone, inferior alvelolar nerve, floor of mouth or 
skin efface, i.e, chin or nose 
T4a: (oral cavity). Tumor invades adjacent structures (eg. Through cortical bone, into 
deep extrinsic muscle of tounge(genioglossus, hyoglossus, palatoglossus, and 
styloglossus), maxillary sinus skin of face 
T4b: Tumor invades masticator space, pterygoid plates or skull base and/or encases 
internal carotid artery 
Regional lymph nodes 'N'-
Nx: Regional lymph nodes cannot be assessed 
NO: No regional lymph node metastasis 
Nl: Metastasis in a single ipsillateral lymph node, more than 3 cm but not more than 6 
cm in greatest dimension; or in multiple ipsillateral lymph nodes, none more than 
6 cm in greatest dimension; or in bilateral or contralateral lymph nodes none more 
than 6 cm in greatest dimension 
N2a: Metastasis in a single ipsillateral lymph node, more than 3 cm but not more than 6 
cm in greatest dimension 
N2b: Metastasis in multiple ipsillateral lymph nodes, none more than 6 cm in greatest 
dimension 
N2c: Metastasis in bilateral or contralateral lymph nodes none more than 6 cm in 
greatest dimension 
N3: Metastasis in lymph node more than 6 cm in greatest dimension 
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Distant Metastasis 'M'-
Mo 
M, 
Distant metastasis cannot be assessed 
No distant metastasis 
Distant metastasis 
Table 2.1: STAGE GROUPING (TNM, 2002) 
Stage 0 
Stage I 
Stage II 
Stage m 
Stage rV A 
Stage IVB 
Stage rvC 
Tis 
Tl 
T2 
T3 
Tl 
T2 
T3 
T4a 
T4a 
Tl 
T2 
T3 
T4a 
Any T 
T4b 
Any T 
NO 
NO 
NO 
NO 
Nl 
Nl 
Nl 
NO 
Nl 
N2 
N2 
N2 
N2 
N3 
AnyN 
Any N 
MO 
MO 
MO 
MO 
MO 
MO 
MO 
MO 
Mo 
MO 
MO 
MO 
MO 
MO 
MO 
Ml 
Histological Differentiation of Oral Squamous Cell Carcinoma 
Oral s e c has been divided histological in to three grades, depending on the loss of 
differentiation. These are: 
• Well differentiated SCC (WD SCC): Possesses cellular maturity and organization 
similar to normal squamous epithelium; with formation of keratin pearls. 
• Moderately differentiated SCC (MD SCC): There is wide range of cytological 
atypia recognizable pricke cells and desmosomes but no keratin production. 
Poorly differentiated SCC (PD SCC): there is marked degree of cytological atypia 
with mitotic activity and cellular pleomorphism, such that there is little or no 
resemblance to the normal squamous epithelium 
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Incidence of Oral Cancer 
Oral cancer is the sixth most common cancer in the world and third most common cancer 
in developing nations and is largely preventable. (Parkin SM et al, 1988; Raubenheimer 
EJ et al, 1989). It accounts for approximately 4% of all cancers and 2% of all cancer 
deaths world wide (Boring CC et al, 1993). In India, it is the most common malignant 
neoplasm accounting for 20-30% of all cancers (Nair UJ et al, 1999). 
Oral cancer is newly diagnosed in approximately 40,000 Americans and 350,000 others 
worldwide each year (Boring et al, 1992). About half of the patients afflicted will die 
within five years of diagnosis, while surviving patients may be left with severe aesthetic 
and/or functional compromise (Silverman S et al, 1988; Yokes et al, 1993, Sidransky, 
1995). 
Although there has been a reduction in total mortality over the past two decades, the five-
year relative cancer survival rate for oral cancer is one of the lowest, far below the rate 
for many other cancers, including skin melanoma and cancer of the testis, breast, colon, 
rectum and kidney. The survival curves of oral cancer have plateaued over the past two 
decades and remain among the worst of all cancer sites. 
Incidence of Oral Cancer in World 
It is well known that certain types of cancer occur at very high rates in certain regions; 
for example cancer of the liver is frequent in parts of Africa but extremely rare in 
America and Europe while nasopharyngeal carcinoma is much more frequent among the 
Chinese than among other people. 
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Areas of high risk for oral cancer in world other than India and South East Asia include 
Central and Eastern Europe and South America. Incidence rates of oral cancer show 
marked geographic variation with the Bas Rhin region in the France having the highest 
recorded incidence of oral cancer in the world. The frequency of oral cancer may be 
expressed as rates per 10,000 population. The incidence rate of oral cancer in high risk 
countries of world is given in Table 2.2. 
Mortality rates, based on cause-of-death registration, are often computed as measure of 
frequency of cancer. This is a less reliable statistic, partly because the various forms of 
cancer exhibit extreme differences in mortality rates, and partly because mortality 
statistics reflect such various factors as ease and efficiency of early diagnosis, therapeutic 
and surgical techniques, etc. Death per 10,000 populations from cancer of oral cavity in 
high risk countries is given in Table 2.3. 
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Table 2.2: Worldwide incidences of oral cancer (Incidence rates) 
Region 
Africa 
Carribean 
America 
Asia 
Europe 
Australia 
Melanesia 
Country 
Ethopia 
Mozambique 
Gabon 
Sudan 
Botswana 
Namibia 
South African Republic 
Puerto Rico 
Brazil 
Canada 
America 
Cambodia 
Lao 
Bangladesh 
Bhutan 
India 
Kazakhstan 
Nepal 
Pakistan 
Sri Lanka 
Turkmenistan 
Yemen 
Belarus 
Hungary 
Slovokia 
Ukarine 
United Kingdom 
Croatia 
Portugal • 
Spain 
Germany 
Australia 
Papua New Guinea 
Solomon Islands 
Age Standardized Rate (ASR) 
Male 
7.7 
2.0 
14.1 
10.6 
23.1 
16.1 
11.2 
10.6 
8.3 
6.9 
7.9 
10.2 
2.6 
13.4 
12.8 
12.8 
14.9 
12.8 
14.7 
24.5 
12.9 
4.6 
12.9 
19.1 
12.2 
12.2 
5.0 
12.5 
13.4 
13.5 
11.1 
11.1 
40.9 
34.1 
Female 
7.9 
7.0 
3.8 
5.7 
9.5 
7.2 
2.9 
2.5 
1.7 
2.9 
3.4 
2.7 
6.1 
16.8 
8.4 
7.5 
2.7 
8.4 
14.7 
9.2 
3.3 
6.4 
1.8 
4.5 
1.8 
1.8 
2.7 
2.7 
2.1 
2.3 
2.8 
4,7 
26.3 
21.7 
Source: International Agency for Research on Cancer, lARC (GLOBOCAN 2002) 
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Table 2.3: Worldwide incidences of oral cancer (Mortality rates) 
Region 
Africa 
Carribian 
America 
Asia 
Europe 
Australia 
Melanesia 
Country 
Ethopia 
Mozambique 
Gabon 
Sudan 
Botswana 
Namibia 
South African Republic 
Puerto Rico 
Brazil 
Canada 
America 
Cambodia 
Lao 
Bangladesh 
Bhutan 
India 
Kazakhstan 
Nepal 
Pakistan 
Sri Lanka 
Turkmenistan 
Yemen 
Belarus 
Hungary 
Slovokia 
Ukarine 
United Kingdom 
Croatia 
Portugal 
Spain 
Germany 
France 
Australia 
Papua New Guinea 
Solomon Islands 
Age Standardized Rate (ASR) 
Male 
4.6 
1.2 
8.5 
6.5 
14.2 
9.8 
6.3 
3.9 
3.0 
1.6 
1.3 
5.3 
1.5 
7.3 
7.1 
7.2 
6.4 
7.1 
7.9 
24.5 
5.7 
2.7 
5.5 
10.8 
7.3 
6.2 
1.6 
5.4 
3.1 
3.0 
2.8 
3.7 
1.8 
22.4 
18.7 
Female 
4.7 
4.2 
2.3 
3.5 
5.8 
4.4 
1.6 
1.0 
0.8 
0.8 
0.6 
1.4 
3.2 
9.4 
4.7 
4.2 
1.3 
4.7 
8.2 
5.1 
1.5 
3.3 
0.6 
1.8 
0.7 
0.6 
0.8 
0.6 
0.6 
0.6 
0.8 
0.7 
0.9 
15.0 
12.4 
Source: International Agency for Research on Cancer, lARC (GLOBOCAN 2002) 
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Incidence of Oral Cancer in India 
It is well known that oral cancer is quite frequent in India accounting for 20-30% of all 
cancers (Nair UJ et al, 1999). Table 2.4 shows relative incidence of oral cancer in 
different parts of India as studied by various researchers. 
Table 2.4: Relative incidences of oral cancer in different parts of India 
Authors 
Wahi-Saxena(I958) 
Paymaster (1957) 
Krishnamurthy(1959) 
Saxena & Agarwal 
(1965) 
Krishna, G. 
e/a/., (1967) 
Mehrotra, R. et al, 
(2003) 
Institution 
S.N.M.C, Agra 
Tata Memorial 
Hospital, Bombay 
Cancer Institute, 
Madras 
J.K Institute of 
Radiology & Cancer 
Research, Kanpur 
L.L.R. Hospital & 
J.K. Institute of 
Radiology & Cancer 
Research, Kanpur 
M.L.N. Medical 
college, Allahbad 
Period of 
Study 
1948-56 
1941-55 
1953-57 
1959-63 
Jan. - Dec. 
1964 
1990-2000 
Total No. of 
Malignancies 
2800 
6077 
3927 
3544 
2811 
40559 
Percentage of 
Oral Cancer 
26.8 
35.9 
39.0 
27.2 
27.6 
18.7 
Incidence According to the Site 
Oral cancer may occur at different sites of oral cavity like buccal mucosa, tongue, palate, 
lips and alveolar region. The frequency of oral cancer according to the site has been 
reported from different parts of the world. Table 2.5 gives a brief review of the incidence 
as reported by various authors. 
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Table 2.5: Incidence of oral cancer in different sites of oral cavity recorded in India 
Place & author 
Bombay- Khanolkar 
(1944) 
Ceylon-Corey (1944) 
Vishakhapatanam- Kini & 
SubbaRao (1937) 
Vishakhapatnam -
Khanolkar & Surya Bai 
(1945) 
Patna- Khanolkar & Surya 
Bhai (1945) 
Agra-Haldar (1953) 
Travanvore-SomerWell 
(1944) 
Bombay- Rao et al., 
(1994) 
Aichi, Japan Takezaki H. 
e/a/., (1996) 
Total 
Cases 
1000 
274 
155 
284 
145 
600 
4497 
713 
266 
Buccal 
Mucosa % 
16.5 
48.5 
16.8 
15.4 
28.0 
54.1 
45.5 
44.2 
49.2 
Tongue 
% 
52.2 
15.7 
32.2 
27.7 
18.2 
26.0 
13.0 
24.6 
-
Palate 
% 
6.2 
5.4 
33.5 
36.8 
11.2 
8.2 
-
3.2 
-
Lips 
% 
1.7 
13.2 
9.0 
7.0 
12.6 
3.4 
6.0 
4.2 
-
Alveolar 
Mucosa % 
6.0 
15.7 
8.7 
4.9 
21.0 
8.3 
35.0 
17.2 
-
Age Incidence 
Age for oral cancer is 5"' and 6* decade as with other cancers and 95% of patients with 
oral cancer are over 40 years of age at diagnosis and mean age at diagnosis is 60 years , 
63.5 years for males and 60.6 years for females(Blot W J e/ al, 1994) 
Age specific incidence rate for 45-49 age group is 3.1 per 10^  while for 70-74 age group 
is 49.2 per 10^  population while incidence of oral cancer in young adults ranges between 
0.4% and 3.6% (Friedlander PL et al, 1988) 
Sex Incidence 
It is widely accepted fact that oral cancers occur more commonly among the males than 
in females (Boring CC et al, 1992; Balaram et al, 2002; Rosenquist et al, 2005; 
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Muwonge et al, 2007). In high risk areas except India, the male: female ratio is between 
3 and 10. In India, incidence has also been reported to be higher among men than women, 
but the sex disparity is much less marked than in Europeans. The sex incidence of oral 
cancer in India has been studied by various researchers as given in Table 2.6. 
Table 2.6: Incidence of oral cancer in different sex groups in India 
Authors 
Subrahmanyam, B. et al., (1954) 
Percentage 
Sbarma (1964) 
Percentage 
Saxena & Agrawal (1965) 
Percentage 
Krishna, G. et al., (1967) 
Percentage 
Sankaranyanan, R. et aL, (1990) 
Percentage 
Rajkumar, T. et al., (2003) 
Percentage 
Mehrotra, R. et al, (2003) 
Percentage 
Muwonge, R. et al, (2005) 
Percentage 
Total Cases 
445 
122 
963 
116 
414 
591 
159 
282 
Male 
279 
62.7 
97 
79.5 
706 
73.3 
552 
71.1 
25.0 
60.38 
308 
52.11 
232 
76.57 
163 
57.8 
Female 
166 
37.3 
25 
20.5 
257 
26.7 
224 
28.9 
164 
39.61 
283 
47.98 
71 
23.43 
119 
42.2 
Etiology 
The etiology of oral cancer is ill understood like any other cancer elsewhere in the body. 
However it has been observed that the varying incidence of oral cancer in different parts 
of the world and in the same parts of the country is due to certain social customs and 
habits predominant in that particular country. 
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The factors that have from time to time been referred as etiological factors responsible for 
oral cancer are tobacco, areca nut, betel quid, alcohol, oral hygiene, diet, socio economic 
status and viruses. 
I. Tobacco 
Tobacco has long been incriminated as one of the main factors causing chronic irritation 
in the buccal cavity in India, Ceylon, Malaysia, Taiwan, Thailand and Indochina (Davis, 
1915). The incidence is unequal in the above countries due to the individual variation in 
the ingredients chewed with tobacco. 
Tobacco either by chewing or by smoking can produce oral cancer. In India, association 
of tobacco chewing and smoking with oral cancer has been demonstrated in various 
studies (Sanghvi et al, 1955; Wahi et al, 1965; Jussawala and Desphaparde, 1971; 
Jayant et al, 1977; Nandakumar et al, 1990; Balaram et al, 2002 etc). 
Tobacco acts as an initiator and promoter of the disease. The relative risk of cancer seems 
to be dose related and early age chewers, chain chewers and night chewers are more 
likely affected. 
Chronic habit of chewing tobacco^etel quid (betel leaf coated with slaked lime wrapped 
around areca nut) and reverse type of smoking (chutta) are causally associated with the 
high incidence of oral malignancies in the Indian subcontinent (Sanghivi et al, 1981). In 
India, tobacco is smoked in the form of cigarette, bidi, cigar/chutta, hukkah, chewed 
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alone or with lime, used as an ingredient in betel quid, inhaled as snuff powder and is 
applied to the gums in form of paste-dentobac, mishri etc. Nearly 2 decades ago, another 
product pan masala has been introduced in India. It is mixture of catechu (about 10%), 
lime (about 1%), areca nut and betel leaf pieces (nearly 80% of the mixture), the 
remaining 9% include menthol and various spices such as cardamom and flavoring agents 
(Sanghivi et al., 1981). Tobacco is added to pan masala after it is made into a thick 
extract, locally known as 'kimam'. It is made from tobacco dust (floor sweepings from 
cigarette factories), veins and midribs of tobacco leaf and cigarette cuttings. Pan tobacco 
chewing is considered to be the most important determinant of oral cancer in South India 
(Sankaranarayanan et al, 1989) and interestingly areca nut, one of main ingredients of 
paan is considered strongest risk factor for oral sub mucous fibrosis, a precancerous 
condition very common in India. Presently, two types of chewing products are available 
i.e pan masala without tobacco, and gutkha, which is a mixture of pan masala and 
tobacco (Chaudhry, 1999). 
Thus, changing pattern of tobacco use, especially with regard to alarming upsurge in 
gutkha consumption, is a major cause of concern for health professionals. Recent reports 
indicate that the incubation period of oral cancer may be shorter with the use of this 
substance (Chaudhary, 1999). Pan masala is popular not only with males but also among 
women and children who generally refrain from tobacco use in any form. In view of the 
rapid upsurge in the incidence of oral precancerous lesions particularly, in the age groups 
(13-30 yeas), in both genders, there is urgent need to undertake molecular epidemiology 
studies pertaining to pan masala consumption in the Indian population. 
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Consumption of pan masala and areca nut has been proposed to have association with 
precancerous lesions such as Oral Submucous Fibrosis (OSMF). There have been no 
studies on the association of gutkha and oral leukoplakia. However, chewing of Manipuri 
tobacco has been shown to be associated with a higher prevalence of oral leukoplakia as 
compared to no chewing (Wahi et al., 1968). Studies have also shown malignant 
transformation of oral leukoplakia to cancer (Mehta et al, 1969, 1972). 
In the Western World, cigarette smoking is responsible for the majority of all tobacco 
related oral cancers. The risk of developing oral cancer is directly related to the intensity 
of tobacco usage (Graham S et al, 1977;La Vechia et al, 1997) with heavy smokers 
(over 20 cigarettes or 5 cigras per day) having a six fold increased risk of developing the 
disease compared to non-smokers (Cawson RA et al, 1996) . Quitting smoking for 10 
years or more reduces the odds ratio for developing oral cancer almost to unity 
(Franceschi S et al, 1990). In the western world, oral cancer is rare in non-smokers 
(Lemon FR era/., 1964). 
Chapman (1961) studied the effect of tobacco smoking in relation to leukoplakia and he 
observed that the length of time of smoking bears strong relation to severity of 
leukoplakia. 
n. Alcohol 
Alcohol has been established as a etiological factor in oral cancer in various studies 
(Rothman & Keller, 1972; Mccoy GD et al, 1979). 
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Alcohol is an independent risk for oral cancer and also acts synergistically with tobacco 
in an additive or multiplicative fashion (Elwood JM et al, 1984). Heavy drinkers (> 30 
drinks per week) and heavy smokers have a relative high risk for developing oral cancer 
i.e. twenty four times greater than non drinkers and non smokers (McCoy GD et al., 
1979). Notani has reported the relative risk associated with combined habits of chewing 
and alcohol intake with or without smoking in Indian population (Notani et al, 1988). 
III. Poor Oral Hygiene 
The standard of oral hygiene in an average patient of oral cancer is very poor. Whether it 
is one of the causes or the effect of growth, is disputable. However oral sepsis specially 
chronic long standing untreated Pyrrhoea alveolus is said to be contributing factor in the 
production of cancer gums. Similarly lack of oral hygiene, as indicated by no use of tooth 
brush, accounted for 32% of oral cancer in men and 64% in women in study conducted 
by Prabha Balaram et al, (2002). 
rv. Diet 
Approximately 15% of oral and oropharyngeal cancers can be attributed to dietary 
deficiencies or imbalances (La Vechia C et al, 1997). In an international ecological study 
of nutrient predicators for oral cancer, the risk level has been shown to increase with 
increasing meat and animal fat consumption and to decrease with fruit and cabbage 
consumption (Hebert et al, 1993). 
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Beta carotene and vatamin E can produce regression of oral leukoplakia. Prolonged and 
heavy consumption of food rich in nitrates and nitrosamines such as preserved meat and 
fish significantly increase lifetime risk for the development of oral cancer as may diets 
low in carotenoids (Garewal HS et al, 1995). 
Frequent consumption of eggs, raw green vegetables, carrots, pulses, apple or pears, 
citrus fruit, and overall consumption of vegetables and fruits decreases oral cancer risk 
(La Vechia C et al, 1993). The risk associated with low consumption of vegetables was 
higher among smokers than among non smokers. 
V. Viruses: 
Of the many viruses that are potential candidates for oral carcinogenesis there is little or 
no evidence at the present time for either the retroviruses, adenoviruses or the Esptein-
Barr virus (Cox MF et al, 1991). There are some date implicating Herpes Simplex 
Viruses (HSV) and the Human Papilloma Viruses (HPV) in the etiology of oral cancer 
(Johnson NW et al, 1993) although; if they do have an oncogenic role it is likely to be 
small. 
Diagnosis and Treatment Modalities 
One of the real dangers of oral cancer is that in its early stages, it can go unnoticed. 
However in its earliest stages, it may appear as a white or red patch of tissue in the 
mouth, or a small indurated ulcer which looks like a common sore. Because there are so 
many benign tissue changes that occur normally in mouth, and some thing as simple as a 
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bite on the inside of cheeic may mimic the look of a dangerous tissue change. Other 
symptoms include; a lump or mass which can be felt inside the mouth or neck, pain or 
difficulty in swallowing, speaking, or chewing, any wart like masses, hoarseness which 
lasts for a long time, or any numbness in the oral/facial region. The most common areas 
for oral cancer to develop are on the tongue and the floor of the mouth. Individuals that 
use chewing tobacco are likely to have them develop in the sulcus between the lip or 
cheek and the soft tissue (gingiva) covering the lower jaw (mandible). The base of the 
tongue at the back of the mouth and the pillars of the tonsils, are other sites where it is 
commonly found. It is important to have a firm diagnosis as early as possible. Usually, a 
biopsy is done with local anesthesia to diagnose the cancerous tissue. Treatment 
modalities include surgery to remove the tumor in the mouth or throat and radiation 
therapy which is used alone for small tumors or for patients who cannot have surgery. It 
may be used before surgery to kill cancer cells and shrink the tumor. It also may be used 
after surgery to destroy cancer cells that may remain in the area and chemotherapy. 
Genetic Susceptibility 
CYP2E1: The gene, CYP2E1, encodes a member of the cytochrome P450 
superfamily of enzymes. The cytochrome P450 proteins are mono oxygenases which 
catalyze many reactions involved in drug metabolism and synthesis of cholesterol, 
steroids and other lipids. This protein localizes to the endoplasmic reticulum and is 
induced by ethanol, the diabetic state and starvation. The enzyme metabolizes both 
endogenous substrates such as ethanol, acetone and acetal, as well as exogenous 
substrates including benzene, carbon tetrachloride, ethylene glycol, and 
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nitrosamines which are premutagens found in cigarette smoke. Due to its more than 
one substrates, this enzyme may be involved in as many processes such as 
gluconeogenesis, hepatic cirrhosis, diabetes as well as cancer. CYP2E1 gene maps 
on chromosome 10, at lOq 24.3. 
Alcohol dehydrogenase-2 (ADH2), aldehyde dehydrogenase-2 (ALDH2) and 
Cyp2El are important enzymes for the catalysis of the conversion of ethanol to 
acetaldehyde and to acetate in humans. Genetic polymorphisms have been reported 
in ADH-2 and ALDH2, as well as in CYP2E1 (Hayashi etal, 1991). Hayashi et al, 
(1991) described a polymorphism in the 5-prime flanking region of Cyp2El, and the 
alleles were designated Ci (Rsal+) and C2 (Rsal-). Sarmanova et al, (2001) 
described another polymorphism in Cyp2El-intron 6 and the alleles were designated 
C [Dral+] and D [Oral-]. 
Tanaka et al, (1997) observed that the individuals with the C2/C2 genotype at 
CYP2E1 locus could consume more ethanol on average than those with the Ci/Ci 
genotypes .In subjects homozygous for the ALDH2*1 homozygous genotype, there 
is an interactive effect between ALDH2 and CYP2E1 on alcohol consumption. To 
evaluate the independent and interactive effects of the genetic polymorphisms of 
ALDH2, ADH2 and CYP2E1 in relation to alcohol consumption large enough to 
cause adverse health effects, Sun et al, (1999) analyzed 643 Japanese men for 
genotype and drinking habits. They showed that Japanese men with the ALDH2*1 
warn 
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homozygous genotype and the C2 allele of CYP2E1 are at a higher risk of showing 
excessive alcohol consumption. 
The development of Oral SCC has been linked to exposure to carcinogens such as 
nitrosamines that cause various alkyl DNA damages. O -^ methylguanine-DNA 
methyltransferase (MGMT) offers a primary defence against alkylation induced 
mutagenesis and carcinogenesis. Because cytochorome P-450 (CYP2E1) is involved 
in metabolic activation of environmental chemical carcinogens, gene 
polymorphisms that alter its function may be associated with cancer susceptibility. 
Genetic polymorphisms of CYP2E1 gene have been reported to determine 
susceptibility to several cancers, including esophageal, gastric, nasopharyngeal and 
breast cancer. In a study by Cai L et ah, 2005, the genetic risk for gastric cardia 
cancer is shown to be associated with CYP2E1 polymorphism. The genetic 
polymorphism of CYP2E1 gene in gastric cardia cancer susceptibility was assessed 
by examining polymorphic prevalence in 159 gastric cardia cancer patients and 192 
healthy controls (who were individually matched to the patients with respect to sex 
and age). It was concluded that CYP2E1 genotype influences individual 
susceptibility to development of gastric cardia cancer and that the risk increases 
significantly in smokers. 
In another study by Itoga et al, 2002, correlation of CYP2E1 Rsal polymorphism 
with susceptibility to esophageal and lung cancer has been described. Enzyme 
genotypes were determined using PCR and restriction enzyme digestion of 
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leukocyte DNA collected from 85 lung cancer patients and 82 esophageal cancer 
patients and 192 healthy controls. The data suggested that CYP2E1 polymorphism 
was associated with esophageal cancer but no association was found in patients with 
lung cancer. The genotype frequencies in 346 breast cancer patients & 377 control 
individuals was assessed by Choi et al., 2003 and it was concluded that CYP2E1 C2 
allele genetic polymorphism is associated with susceptibility to breast cancer in 
alcohol-consuming women. 
In another population based study by Kongrutanachok N et al, (2001), the 
association of CYP2E1 polymorphism with development of nasopharyngeal 
carcinoma in Thailand was assessed. It was concluded that there is correlation 
between the Rsal homozygous genotype in the CYP2E1 gene and a higher relative 
risk of nasopharyngeal carcinoma development in the Thai or Chinese population in 
Thailand. 
A case control study of 99 Indian leukoplakia patients along with 227 healthy 
controls was conducted by Sikdar et al, (2003) to assess any association between 
CYPIAI and CYP2E1 polymorphisms, either separately or in combination, with the 
likelihood of development of leukoplakia in this population. The frequencies of 
genotypes at polymorphic sites in CYPlAl and CYP2E1 genes, were similar in 
patients and control groups but the combined rare and homozygous genotypes 
(CC+DD) at the Dral site in the CYP2E1 gene were over expressed among patients 
compared with controls (OR=2.02, 95% confidence interval (CI)=1.21-3.35). Light 
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tobacco smokers (i.e. <21 pack per year) and light tobacco chewers (i.e. 104 
chewing per year) with a "rare" C allele at the Dral site had high risk of leukoplakia 
(OR=2.88, 95% Cl = l.16-7.22; OR=2.94, 95% CI=1.15-7.65 respectively). The 
"mixed tobacco" users with "rare" C allele are more susceptible to the leukoplakia 
than "exclusive" tobacco smokers and chewers. These results indicate that the "rare" 
C allele at the Dral polymorphic site in CYP2E1 gene may enhance susceptibility to 
leukoplakia among tobacco users in this population. 
In another study by liu et al, 2001 the role of CYP2E1 Rsal/Pstl polymorphism as 
risk factor for oral cancer was elucidated in 570 patients. It was shown that a 
significant increase in CYP2E1 (Cl/Cl Rsal) genotype was observed in oral cancer 
cases as compared to frequency matched controls in subjects who smoked less than 
24 packs per year (p=0.33). No association was observed between CYP2E1 
genotype and risk for oral cancer in the heavy smoking group (i.e., > 24 packs per 
year). These data suggest that the Ci Rsal polymorphism contributes to increased 
risk for oral cancer. 
To investigate whether alcohol dehydrogenase 3 (ADH3) and CYP2E1 Dral and 
Rsal genotypes modify the risk of upper acrodigestive tract cancers, Bouchardy et 
al, 2000 studied 127 laryngeal cancer and 121 oral cavity/pharyngeal cancer 
patients and 172 healthy controls. The results revealed that alcohol dehydrogenase 3 
(ADH-3) was not associated with UAT cancer. In contrast, a two fold risk of oral 
cavity/pharyngeal (OR=2.0, 95% CI=1.0-3.9) and laryngeal (0R=1.8, 95% CI= 1.0-
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3.5) cancers was observed for carriers of the CYP2E1 Dral C variant allele 
compared with other individuals. The risk associated with the CYP2E1 Rsal C2 
variant allele also increased for oral cavity/ pharyngeal cancer (OR=2.6, 
95%Cl = 1.0-6.6). The highest risk of oral cavity/pharyngeal cancer was among the 
heaviest drinkers (>80g/day) with the CYP2E1 Dral C allele (OR=5.8, 95% Cl = 1.9-
18.2) or the CYP2E1 Rsal C2 allele (OR=7.2, 95% Cl = l.4-38.2) compared with 
lighter drinkers with other genotypes. The data suggested that CYP2E1 genotype 
modifies the risk of upper aero digestive tract cancers. 
In another study by Hung et ai, (1997), the role of allelism at the GSTMI, GSTII 
and CYP2E1 loci in determining individual susceptibility to oral cancer has been 
described. Enzyme genotypes were determined using polymerase chain reaction and 
restriction enzyme digestion of leukocyte DNA collected from 41 male oral cancer 
patients and 123 healthy controls. The data suggested that null genotype of GSTMI 
and/or GSTII is associated with an increased oral cancer risk. Besides CYP2E1 
C1/C2 and C2/C2 genotypes were associated with a significantly increased oral 
cancer risk compared with the Cl/Cl genotype among those who did not chew betel 
quid (OR=4.7; 95% C 1=1.1-20.2), but not among betel quid chewers. Habitual 
alcohol drinking was associated with significantly increased oral cancer risk, 
showing an OR of 3.0 (95% C 1 = 1.8-8). 
In another study by Gattas et al, 2006, the role of metabolic enzyme 
polymorphisms on the risk of head and neck cancer in a hospital based case-control 
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study was evaluated. CYPlAl Mspl, CYP2E1 PstI, GSTMl, and GSTTl 
polymorphisms were evaluated in 103 histologically confirmed head and neck 
cancer cases and 102 controls. GSTMl null genotype increased the risk of head and 
neck cancer (OR =2.2, 95% CI=1.24-3.79), oral cancer (OR=2.8; 95% CI=1.28-
5.98), and pharyngeal cancer (OR=2.2; 95% CI= 1.29-11.56). The joint effect of 
GSTMl null and CYPIAI polymorphisms increased the risk of head and neck cancer 
(OR =2.4; 95% CI= 1.13-5.10). 
hOGGI and XRCCI: Human OGGI (hOGGI) and XRCCI are two of the important 
enzymes participating in the BER (Base Excision Repair) pathway, the DNA repair 
system involved in the repair of damage resultant from oxidative stress. The Human 
OGGI (hOGGI) gene is located on chromosome 3p26.2, a region that frequently 
shows loss of heterozygosity in several human cancers (Shinmura et ah, 2001, 
Kohno et al, 1998). Human OGGI gene consists of seven exons and six introns and 
encodes a 345 amino acid, a bi-functional glycosylase. Human OGGI can recognize 
and excise, 8-oxoguanine, the major form of oxidative damage induced by free 
radicals (Bruner S.D. et al, 2000). 8-oxoguanine is able to base pair with adenine 
and cause GC-AT transversion in repair-deficient bacteria and yeast (Demple B, 
Harisson L 1994). At least 20 sequence variants have been described and among 
these, a C-G sequence variant leading to an amino acid change from serine to 
cysteine at codon 326 (ser 326 Cys) has been studied most frequently. 
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XRCCI (X-ray repair cross complement group 1) gene is located on chromosome 
19q 13.2 and consists of 17 exons and encodes a protein of 633 amino acids 
(Lindahl et ah, 1999). The XRCCI protein is essential for mammalian viability and 
its deficiency in mice results in embryonic lethality. XRCCI is required for the 
efficient repair of single strand breaks and damaged bases in DNA. XRCCI has no 
known enzymatic activity, and it is thought to act as a scaffold protein for both 
single-strand break repair and base excision repair activities (Lindahl et al, 1999). 
XRCCI complexes with DNA polymerase fi via the NH2 terminus domain and with 
DNA lagase 111 via a blue ribbon commission on transportation (BRCT) domain to 
repair nicks or gaps left in the BER pathway (Nash R.A. et al, 1997). XRCCI has 
also been shown to be involved in the detection of single strand breaks between 
incision and ligation, and effect that likely occurs via poly (ADP-ribose) polymerase 
dependent and poly (ADP-ribose) polymerase independent mechanisms (Masson M 
et al, 1998). More than 60 validated single nucleotide polymorphisms in XRCCI 
gene have been described and among these, the most extensively studied single 
nucleotide polymorphisms are Arg 194 on exon 6, Arg 280 His on exon 9, and Arg 
399Glnonexon 10. 
In a case-control study of 169 orolaryngeal cancer patients and 388 healthy controls 
by Elahie et al, (2002), the results suggested that hOGGI Ser 326 Cys 
polymorphism plays an important role in risk for smoking and alcohol related 
orolaryngeal cancer. Significantly increased risk for orolaryngeal cancer was 
observed for both the hOGGI/326(Ser)/326(Cys) (OR=1.6,95%(CI)= 1.04-2.6) and 
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hoGGI/326(Cys)/326(Cys) (OR=4.1,95% CI=1.3-7.3) genotypes while increased 
risk for orolaryngeal cancer was observed for the hOGGI 326(Cys)/326(Cys) 
genotype in smokers (>100 cigarettes lifetime, OR=4.8,95% CI=1.3-8) and alcohol 
drinkers (>1 shot/weak, OR=6.9, 95% CI= 1.6-2.9). 
In a study by Park J et al., 2004, the genetic risk for lung cancer was shown to be 
associated with hOGGl Ser 326 Cys polymorphism. The genetic polymorphism of 
hOGGI gene in lung cancer susceptibility was assessed by examining polymorphic 
prevalances in 179 Caucasian lung cancer patients and 358 healthy controls. 
Significantly increased risk for lung cancer was observed for both hOGGI 326 
(Ser)/326(Cys) (0R=1.9, 95% CI= 1.2-2.9) and hOGGI 326 (Cys)/326(Cys) 
(0R=1.7, 95% CI=l.l-2.8) genotypes. 
The genetic polymorphism of hOGGI gene among 84 prostrate cancer patients was 
investigated by Chen et al, (2003), to evaluate the role of genetic susceptibility in 
prostrate cancer. A significant association was found between hOGGI genotypes and 
prostrate cancer with a dose effect relationship (P<0.003). A significantly increased 
risk of prostrate cancer was observed for subject with hOGGI (326 Cys) allele 
(OR=2.1,95%CI=1.2-3.8). 
In another study by Jiaox et al, (2007), the role of hOGGI Ser 326 Cys 
polymorphism in determining individual susceptibility to gallbladder cancer has 
been described. Genotype assays were determined using polymerase chain reaction-
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Restriction fragment length polymorphism (PCR-RFCP) method from 204 patients 
and 209 controls. The data suggested that hOGGI 326 Cys polymorphism is 
associated with gallbladder cancer risk but this association was not found in 
gallstone absence. 
A community based case control study of 109 lung cancer patients along with 109 
healthy control subjects, individually matched on age and gender, was conducted in 
China by Chen et al, (2002), to assess any association between XRCCI and XPD 
polymorphisms with the likelihood of development of lung cancer in this 
population. The results revealed that XRCCI 194 Trp/Trp genotype was associated 
with a borderline increased risk of lung cancer [OR =3.06, 95% CI=0.94-9.92] 
suggesting that XRCCI 194 Trp/Trp might be the risk genotype for lung cancer in 
Chinese population. In another study by Shen et al., (2003), the role of DNA repair 
gene polymorphisms on the risk of bladder cancer in a hospital-based case control 
study was evaluated. XRCCI, XRCC3 and XPD polymorphisms were evaluated in 
201 bladder cancer cases and 214 controls. The results suggested that XRCC3 codon 
241 variant genotype exhibited a protective effect against bladder cancer which was 
more prominent among heavy smokers while XPD polymorphism was not 
associated with bladder cancer. XRCCI codon 399 polymorphism had a protective 
effect on bladder cancer among heavy smokers only (OR=0.38, 95%CI=0.14-1.02). 
A hospital based case-control study was conducted in India to determine the 
interaction between XRCCI (codon 280) and GSTM3 polymorphisms and tobacco 
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use in oral leukoplakia and oral cancer by Majumder et ai, 2005. The results 
revealed that variant haplotypes, containing one variant allele on XRCCI increased 
the risk of leukoplakia (0R=1.3, 95% CI=1.0-1.7) while mixed tobacco users, 
containing variant haplotypes, also had increased risk of both leukoplakia (OR=2.2, 
95% CI=1.3-3.9) and oral cancer (0R=1.9, 95% CI=1.2-1.3). Besides, the 
simultaneous presence of 2 risk genotypes in smokers, one on each of two loci, 
GSTM3 and XRCCI (codon 280) increased the risk of cancer (OR=2.4, 95% 
CI=1.0-5.8). Therefore presence of variant haplotypes on XRCCI and two risk 
genotypes, one on each of two loci, GSTM3 and XRCCI (codon 280) could be 
useful to determine the leukoplakia that might progress to cancer in a group of 
patients. 
In a study by Ramachandran et ai, 2006 on 110 oral cancer, 84 leukoplakia and 110 
controls belonging to Travancore South Indian population, the results revealed the 
association of XRCCI 194 Trp, XRCCI 399 Gin and XPD 751 Gin polymorphisms 
with increased risk of oral cancer. In another study by Kietthubthew et al., (2006), 
the role of polymorphism of DNA repair genes on the risk of oral squamous cell 
carcinoma in Thailand community was evaluated. XRCCI (Arg 194 Trp and Arg 
399 Gin), XRCC3 (Thr 241 Met), XPC (PAT and Lys 93 Gin), XPD (exon 6 and 
Lys 751 Gin) and MGMT (Trp 65 Cys and Leu 8 phe) polymorphisms were 
evaluated in 106 histological confirmed OSCC patients and 164 healthy controls 
that were frequency-matched by age (+/- 5 years), gender, and cigarette smoking 
and alcohol drinking habits. The results revealed that XRCC3 241 Met genotype 
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exhibited a three fold elevated risk (OR=3.3, 95% CI=1.31-8.36, p=0.01) for OSCC 
in Thailand. There was a marginally significant risk observed in variants with 
XRCCI 194 Trp (0R=1.81, 95% CI=0.91-3.63, P=0.09) and XPD exon 6 (0R=1.71, 
95% CI=0.93-3.16, P=0.09). The joint effect of XRCC3 324 Met, XRCCI 194 Trp 
and XPD exon 6 polymorphisms increased the risk of OSCC (OR=3.93, 95% 
Cl = l.14-13.6, P<0.05). 
A population-based case control study was conducted in United States by Gal TJ. et 
al. 2005, to assess the effect of polymorphisms of DNA repair genes (XRCCI, 
XRCC3, XPD and MGMT) on second primary neoplasm and mortality in OSCC. 
Genotype assays were determined using the polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP) method from 279 OSCC patients. The 
data suggested that polymorphism of XRCC3 241 Met gene was associated with an 
increased risk of second neoplasm, and polymorphism of the XRCCI 399 Gin gene 
was associated with a decreased risk of all-cause mortality in patients with primary 
OSCC. 
A case control study of 237 OSCC patients was conducted in Taiwan by Hsieh et 
al, 2003 to evaluate the association of XRCCI 399 Gin polymorphism with 
frequency of P53 mutations. The OSCC patients with a Gln/Gln genotype exhibited 
a significantly higher frequency of p53 mutation than those with an Arg/Gln and 
Arg/Arg genotype (OR=4.5, 95%CI=1.52-13.36). These findings support the 
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hypothesis that XRCCI Arg 399 Gin change may alter the phenotype of the XRCCI 
protein, resulting in a DNA repair deficiency. 
Molecular Basis of Human Oral Cancer 
Carcinogenesis is a complex, multi-step process in which genetic events within 
signal transduction pathways governing normal cellular physiology are 
quantitatively or qualitatively altered (Vogelstein and Kinzler, 1993). The genetic 
basis of cancer is now well-established. Under normal conditions, these tightly 
controlled excitatory and inhibitory pathways regulate oral keratinocyte biology. 
Basic cellular functions under these controls include cell division, differentiation, 
senescence, and adhesion. These regulatory pathways are composed of extra cellular 
ligands which bind to cell-surface receptors to generate intracellular signals sent 
through secondary messengers. These signals either directly alter cell function or 
stimulate the transcription of genes whose proteins effect change (Bishop, 1991). 
Cancer is the result of an accumulation of changes in the excitatory and inhibitory 
cellular pathways, which may occur at any level of a given pathway. It has been 
estimated that from three to six somatic mutations are needed to transform a normal 
cell into its malignant counterpart (Vogelstein and Kinzler, 1993). As the cell 
accumulates these alterations or mutations, it becomes functionally independent 
from the surrounding oral epithelium made up of normal oral keratinocytes 
(Sidransky, 1995). The normal cellular functions tightly controlled by these 
regulatory pathways are subverted in tumor cells, thus enhancing the cell's ability to 
proliferate, stimulate neo-vascularization, and grow by invading locally or 
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metastasizing to distant sites (Weiner and Cancer, 1994). The histological 
progression of oral carcinogenesis is believed to reflect the accumulation of these 
changes (Field, 1992; Yokes et al, 1993). 
Cytogenetics of Human Oral Cancer 
In 1914, Boveri's study of tumor cell chromosomes led him to propose that 
alterations in chromosomes resulted in conversion of normal to malignant 
proliferation (Boveri, 1914). For human oral cancer, the karyotypes of 63 short-term 
cultured tumors have been described (Owens et al, 1992; Jin and Mertens, 1993). 
All karyotypes are complex, with great heterogeneity. Nonetheless, some genomic 
sites seemingly are non-randomly involved. There is the recurrent loss of 
chromosomes 9, 13, 18, and deletions are frequently involved in the chromosome 
arms of 3p, 7q, 8p, llq, and 17p, and in the short arm of all acrocentric 
chromosomes while chromosomes break points are frequently seen in the 
centromeric regions of chromosomes 1, 3, 8, 14, 15 and in bands Ip22, IIql3, and 
19pl3 (Field, 1992; Jin and Mertens, 1993). Since the cellular oncogenes bcl-l, int-
2, and hst-l have been mapped to 1 lql3, while N-ras has been mapped to Ip22, it is 
proposed that activation of the oncogenes located in these bands may be preceded 
by cytogenetic mechanisms. 
Approximately two-third of all head and neck cancer cells contain a deleted region 
located in chromosome 9p21-22 (Ahsee et al, 1994; Nawroz et al, 1994), which 
appears in dysplastic and carcinoma in situ (CIS) lesions, thereby suggesting that a 
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gene in this region is knocked out early in oral carcinogenesis (Van der Riet et al, 
1994). A tumor suppressor gene (TSG) initially isolated from melanoma cells, pl6 
(MTSI or CDKN2), is also found in this region and may prove to be a cell-cycle 
inhibitor important in oral cancer development (Serrano and Hannon et al, 1993; 
Kamb et al, 1994; Van der Riet et al, 1994). Chromosomal regions in 3p and Ipl 
also contain regions frequently deleted and may yield new tumor suppressor genes 
of oral carcinogenesis (Sidransky, 1995). 
Genetic damage in oral cancer cells can be divided into two categories,dominant and 
recessive changes. Dominant changes, most frequently occurring in proto-oncogenes 
but also in certain tumor suppressor genes (TSGS), resuh in gain of function. 
Recessive changes, mutations most frequently noted in growth-inhibitory pathway 
genes or commonly in tumor suppressor genes, cause loss of function (Bishop, 
1991). 
Oncogenes Implicated in Human Oral Cancer 
Oncogenes, gain-of-function mutations of highly regulated normal cellular 
counterparts (proto-oncogenes), are likely involved in the initiation and progression 
of oral neoplasia (Field, 1992). Cellular oncogenes were initially discovered by the 
ability of tumor cell DNA to induce transformation in gene transfer assays (Shih et 
al, 1981). These experiments have led to the identification of more than 60 cellular 
oncogenes (Cooper, 1995). Mechanisms of activation of these cellular oncogenes 
include point mutations and DNA re-arrangements. 
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Several oncogenes have been implicated in oral carcinogenesis (Field, 1992). 
Aberrant expression of the proto-oncogenes, epidermal growth factor receptor 
{EGFR)/c-erh 1, members of the ras family, as well as c-myc-, int-2, hst-\, PRAD-1 
and bcl-\, is believed to contribute to oral cancer development (Berenson et al, 
1989; Wong et al, 1989; Merritt et al, 1990; Riviere et al, 1990; Somers et al, 
1990; Sidransky, 1995). Overexpression of bcl-2 and bax has been reported in 
squamous cell carcinoma (Staibano et al, 1998; Xie et al, 1999). It has been shown 
that TGF-a is aberrantly expressed in human oral cancer and in hamster oral tumor 
(Wong et al, 1998; Todd et al, 1989, 91) and it has been postulated that TGf-a 
promotes neo-vascularization and mitogenesis (Elovic et al, 1990). 
1. Growth factors 
Growth factors can stimulate oral keratinocyte proliferation (Aaronson, 1991; Issing 
et al, 1993). During oral carcinogenesis, growth factors are de-regulated through 
increased production and autocrine stimulation (Sporn and Todaro, 1980; Wong et 
al, 1990; Todd et al, 1991). TGF- a is overexpressed early in oral carcinogenesis 
by hyperplastic epithelium and later by the inflammatory infiltrate, particularly the 
eosinophils, surrounding the invading oral epithelium (Chang et al, 1989; Todd et 
al, 1991). The increase in eosinophils in oral cancer — up to 17% of the total 
inflammatory infiltrate -was noted as early 1975 by Healy (Healy, 1975), and this is 
a consistent feature in all cases of oral cancer examined. TGF-a is a 50-amino-acid 
polypeptide that promotes cell proliferation in oral tissues as well as in other cell 
types in the body. TGF-a stimulates a target cell by binding to the epidermal growth 
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factor receptor (EGFR) in an autocrine or paracrine fashion (Derynck, 1992). 
Overexpression of this growth factor in transgenic mice led to epithelial hyperplasia 
and malignant transformation of mammary epithelium (Jhappan et al, 1990; Matsui 
et al, 1990; Sandgren et al., 1990). In addition, TGF-a likely serves a tumor-
promoting role in epithelial carcinogenesis (Sandgren et al., 1993; Coffey et al., 
1994). In head and neck cancer patients who later develop second primary cancers, 
"normal" oral mucosa oversecretes TGF-a suggesting a "premalignant" state of 
rapid proliferation and genetic instability of the epithelium (Grandis and Tweardy, 
1993). Concomitant expression of TGF-a and EGFR may indicate more aggressive 
tumors than those overexpressing EGFR alone (Issing et al., 1993). 
2. Cell-surface receptors 
Ligand receptor binding activates a cascade of intracellular biochemical steps 
(Aaronson, 1991). Regulation of protein phosphorylation is an important event in 
cellular function and gene expression. Mutations of genes encoding cell-surface 
receptors can result in an increased number of receptors or production of a 
constituent ligand-independent mitogenic signal (Bishop., 1991; Cantley et al., 
1991; Hunter., 1991). 
EGFR, the biological receptor of EGF and TGF-a, is a 170,000-dalton 
phosphoglycoprotein frequently found to be overexpressed in human oral cancers 
(Partridge et al., 1988; Shin et al., 1990; Todd et al., 1991; Rikimaru et al., 1992; 
Saranath et al., 1992; Grandis and Tweardy, 1993). Malignant oral keratinocytes 
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possess from 5 to 50 times more EGER than their normal counterparts (Christensen 
et al, 1993). Currently, three mechanisms have been postulated to activate the 
EGER gene in carcinogenesis: (1) deletions or mutations in the N-terminal ligand-
binding domain such as those occurring in the viral oncogene v-erbB (Downward et 
al, 1984; Ullrich et al, 1984); (2) over expression of the EGFR gene concurrent 
with the continuous presence of EGF and/or TGF-a (Di Fiore et al, 1987; Di Marco 
et al, 1989); and (3) deletion in the C-terminus of the receptor, which prevents 
down-regulation of the receptor after ligand binding (Wells et al, 1988; Batra et al, 
1994). It is therefore of great importance to conduct studies to determine the 
spectrum of mutations in the human EGFR gene in order to gain a better insight into 
the mechanisms responsible for the over expression of this frequently activated 
biomarker in human oral cancer. The molecular mechanisms responsible for the 
over expression are not fully understood. EGFR gene amplification is detected in 
about 30% of cases (Scully, 1993), which suggests that other mechanisms are 
responsible for the majority of EGFR over expression. Whether the mutation in the 
EGFR gene results in over expression of normal receptors or formation of receptors 
that can signal without stimulation or a combination of the two in oral cancer has 
not been understood. Oral tumors overexpressing EGFR exhibit a higher proportion 
of complete responses to chemotherapy than tumors with low-level EGFR 
expression. Over expression of EGFR presumably due to higher intrinsic 
proliferative activity could result in higher sensitivity to drug therapy cytotoxic to 
cells undergoing mitogenesis (Santini et al, 1991). 
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3. Intracellular messengers 
Intracellular messengers can also be intrinsically activated, thereby delivering a 
continuous rather than a ligand-regulated signal (Cantley et ai, 1991; Hunter, 
1991). Of all the members of the intracellular signaling pathway, members of the ras 
gene family (H-ras, K-ras) have been extensively examined in human oral cancer. 
The ras oncogenes were first identified in the murine Harvey and Kirsten sarcoma 
retroviruses. They all encode for the related protein p21 that has been localized to 
the cytoplasmic side of the cellular membrane. Of importance is the realization that 
the ras proteins bind guanine nucleotides (GDP and GTP) with high affinity and 
specificity. The ras proteins were eventually shown to be analogous to the G 
proteins in coupling receptors to intracellular secondary messengers (Shih et al, 
1980). The ras proteins transmit mitogenic signals by binding to GTP. Hydrolysis of 
GTP to GDP ends the signal. Members of the ras gene family are mutated in 
approximately 30% of all human tumors (Bos, 1989). A report from India 
demonstrated that 35% of oral squamous cell carcinomas contained H-ras mutations 
(Saranath et al., 1991). However, studies from the Western world have shown that 
H-ras mutations are found in fever than 5% of head and neck cancers (Rumsby et 
al, 1990; Sheng et al, 1990; Chang et al, 1991). In oral cancer, Kirsten ras (k-ras) 
has been shown to be activated, by a point mutation (Spandidos et al, 1985). Thus, 
it remains activated, but unable to hydrolyze GTP due to an amino acid change 
resulting from this mutation (Barbacid, 1987). Because K-ras cannot convert GTP to 
GDP, it continues to stimulate the cell to proliferate. In a hamster oral cancer model, 
the c-Ha-ras and the c-erbB oncogenes were shown to be sequentially expressed 
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during oral carcinogenesis (Husain et al, 1989). Mutation in codon 61 of the Ha-ras 
gene was identified as an early event in this rodent oral cancer model (Kwong et al, 
1992). 
4. Transcription factors 
Transcription factors, or proteins that regulate the expression of other genes, are 
also altered in oral cancer. Modulation of gene expression is an important outcome 
in the alteration of the intracellular pathways (Bishop, 1991). The transcription 
factor C-myc, which codes for a nuclear protein p62 and helps in regulating cell 
proliferation and differentiation, is frequently over expressed in oral cancers 
(Spandidos et al, 1985; Field, 1992). Over expression due to gene amplification of 
C-myc is most frequently associated with poorly differentiated tumors and with poor 
prognosis (Schantz, 1995).There is overexpression of p53 and C-myc proteins in 
advanced stages of betel and tobacco releated oral squamous cell carcinomas (Baral 
et al, 1998). Overexpression of transcriptional factors, C-raf and C-jun in oral 
cancer has also been reported. Product of C-raf oncogene is a cytoplasmimc serine 
theonine kinase and has been shown to be implicated in drug and radiation 
resistance (Kasid U et al, 1987; Burt RK et al, 1988) while product of C-jun 
oncogene is postulated to have DNA binding activity (Xanthoudakis et al, 1994) 
.Another transcription factor, PRADI (also called CCNDI or cyclin DI), a cell-cycle 
promoter, is also amplified in head and neck cancers. 
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While no particular order of oncogene activation has been demonstrated in oral or in 
other cancers, the accumulation of activated oncogenes appears to be of primary 
importance (Sidransky, 1995). The importance of the presently identified 
oncoproteins to oral carcinogenesis is currently under investigation. Other 
oncogenes linked to oral cancer development are fet-1, int-I, bd-\, sea, men 1, and 
emsA (Field, 1992; Yokes et al., 1993). However oncogenes alone are not sufficient 
to cause oral cancer but appear to be initiators of the process. The critical event in 
the transformation of a premalignant cell to a malignant cell is the inactivation of 
cellular negative regulators, tumor suppressor genes. 
5. Tumor Suppressor Gene (TSG) 
Tumor suppressor genes or anti-oncogenes have been documented to confer potent 
negative regulatory controls which are lost due to chromosomal alterations during 
tumor formation. Functional loss of multiple tumor suppressor genes is believed to 
be the major event leading to the development of malignancy (Lee, 1993; Yokota 
and Sugimura, 1993). Unlike oncogenes, which can effect a cellular change through 
mutation of only one of the two gene copies, tumor suppressor genes are most often 
inactivated by point mutations, deletions, and rearrangements in both gene copies in 
a "two-hit" fashion. Therefore, the critical events for the malignant transformation 
of oral keratinocytes, i.e. the loss of function of tumor suppressor genes, are 
difficult to achieve. This may account, in part, for the length of time required for the 
formation of adult solid tumors. 
CHAPTER 2: LITERATURE REVIEW 5 3 
Many tumor suppressor genes were initially identified in pediatric tumors that 
formed early in life because one mutated tumor suppressor gene had been inherited. 
However, identification of these genes lagged a decade behind the isolation of the 
first oncogenes, because, in cancer cells, tumor suppressor genes are negative 
phenotypes- an event no longer present within the cell. Knudson predicted that the 
inactivation of both copies of tumor suppressor genes occurs in a two-hit fashion 
(Knudson, 1977). Experimental evidence followed with the observation that normal: 
tumor hybrids demonstrated normal phenotypes, which suggested that normal cells 
contained suppressors of the tumor phenotype (Stranbridge, 1981). These same 
experiments have been performed with normal and malignant oral kerationocytes 
(Moroco et al, 1990). Only after extensive "Chromosomal walking" analysis of 
pediatric tumors with large chromosomal alterations were the first tumor suppressor 
genes isolated (Bookstein and Lee, 1991). Therefore, while the identification of 
these "cancer genes" is one of the primary focuses of tumor biologists today, far 
less is known about tumor suppressor genes. p53, doc-I and thromobospondin 1-
have been studied extensively for tumor suppressor activity in malignant oral 
keratinocytes (Rastinejad et al, 1989; Good et al, 1990; Liu et al, 1994; Todd et 
al, 1995). 
p53, the product of tumor suppressor gene TP53 and localized on 17p 13.1, has a 
central role in the control of the cell cycle of cells bearing sub lethal damage within 
their genome. It arrests the cell cycle in the late Gi phase until repair of the genomic 
damage or causes induction of apoptosis (Cordon Cardo et al, 1995; Hartwell L. et 
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al, 1992; Yonish-Rouache E. et al. 1991; Attardi LD et ai, 1996). p53 is involved 
in DNA synthesis and repair, genomic plasticity, programmed cell death and 
negative regulation of cell cycle (Donehower L.A & Baradley. A., 1993) and is 
called "Guardian of the Genome" (Chang F et al., 1993; Greenblatt MS et al., 1994; 
Lane DP et al., 1992). Loss of tumor suppressor gene function due to mutations in 
the p53 tumor suppressor genes are among the most frequent genetic changes 
detected in human cancers especially in development of head and neck cancer 
(Greenblatt et al., 1994; Harris., 1996; Sidransky and HolIstein,1996; Liloglou et al., 
1997). More than 85% of the p53 mutations are missense mutations and fall within 
exon 5 through 8 that code for the internal and most conserved part of the p53 
protein. Overexpression of the p53 protein was found to be associated not only with 
oral cancers and premalignant lesions (Yan JJ et al., 1996; Chiba I et al., 1998; 
Murti PR et al., 1998) but also with the histological grade of malignancy (De Araujo 
VC et al., 1997) suggesting that p53 alteration is an early event in oral 
carcinogenesis (Kaur et al., 1994). The carcinogenic pathway of overexpressed p53 
protein has been suggested to synergize with bcl-2 overexpression which occurs 
early in oral carcinogenesis resulting in defective apoptosis and subsequent tumor 
progression (Ravi D etal., 1996). 
In normal cells, wild type p53 protein has a very short half life, 6-20 minutes 
(Chiang CP et al., 1999) and is present in such small quantities that it can not be 
detected by Immunohistochemical methods. However, misense mutations in the p53 
gene often result in a more stable gene product and prolong the half life of the p53 
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protein, causing it to accumulate within cell nuclei to the extent that it can be easily 
detected by means of immunohistochemistry. Therefore, positive p53 staining has 
been proposed as an indirect indicator for mutations of the p53 gene (Bennett WP et 
al, 1991). Increased amount of the p53 protein have been found in wide variety of 
human tumors, such as carcinomas of breast, colon, stomach and uterus, and in 
melanomas and soft tissue carcinomas (Bartek et al., 1991). 
Mutation of p53 allow tumors to pass through the Gl-S boundary and propagate the 
genetic alterations that lead to other activated oncogenes or inactivated tumor 
suppressor genes. The p53 gene appears to be mutated at the transition of superficial 
to invasive carcinoma (Sidransky et al, 1993). Alteration of the p53 gene occurs as 
point mutations and deletions. Point mutations result in a structurally altered protein 
that sequesters the wild-type protein, thereby inactivating it in a "dominant-
negative" fashion. Deletions lead to a reduction and loss of p53 expression and 
protein function. Not only has p53 been demonstrated to be functionally inactivated 
in oral tumors, but also restoration of p53 function in oral cancer cell lines and in 
oral tumors induced in animal models results in the reversion of the malignant 
phenotype, thereby turning back oral carcinogenesis (Schantz, 1995). 
It should be noted that p53 has been shown to interact with the oncogenic protein E6 
of the human papilloma virus (HPV), which results in the rapid degradation of the 
p53 protein by the ubiquitin-mediated proteolysis system (Scheffner et al., 1990; 
Werness et al., 1990). Multiple lesions of HPV infection have also been found in the 
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patients with oral cancer and betel quid chewers, and it was suggested that viral 
infection was an important etiological component, with betel quid probably causing 
additional mutagenic steps in the carcinogenic processes (Balaram P et ah, 2002). 
Similar interaction has been shown for the HPVE7 protein with pRB (Dyson et al., 
1989), which interferes with the regulation of the activity of the E2F transcription 
factor family, a phenomenon that has profound consequences for the proliferative 
pattern of the affected cells. The p53 gene appears to be one of the molecular targets 
of tobacco related carcinogens in head and neck squamous cell carcinoma (Kaur et 
al, 1998). Smoking and tobacco use have been associated with mutation of the p53 
gene in squamous cell carcinoma (SCC), of -the head and neck. By 
immunohistochemistry, p53 overexpression has been shown in oral tumors from 
patients who were heavy smokers and chewers (Langdon and Partridge, 1992). 
Polymerase chain-reaction (PCR) has been used to show an association between a 
history of tobacco use and a high frequency of p53 mutations in patients with SCC 
of head and neck (Brennan et al, 1995). Other tumor suppressor gene having role in 
oral cancer, (doc-1) (deleted in oral cancer -1), was identified by Todd et al, (1995) 
using hamster oral cancer model. 
Cyclin Dl gene (CCNDI, bcl-1 or PRADl gene) located on chromosome llq 13 
(Carlos et al, 2002) encodes a protein forming a complex with cyclin- dependent 
Kinases, CDK4 and CDk6. Cyclin D-CDK4 and CDK6 complexes phosphorylate Rb 
protein during the Gi-S transition which leads to their dissociation from the E2F 
transcription factor and the intiation of DNA replication (Michalides RJAM et al. 
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1999; Kudo Y et al, 2000) .Cyclin Dl overexpression, either by amplification or by 
transcriptional upregulation, shows accerelated Gi progression and cell enters in the 
S phase, with lower cell dependence on growth factors for proliferation (Kuo MY et 
al, 1999). This overexpression has been reported in a variety of human tumors, 
including head and neck squamous cell carcinomas (Motokura T et al, 1993)and is 
correlated with cytological grade, infiltrative growth pattern and metastasis 
(Williams HK et al, 2000). 
Several studies (Lam KY et al, 2000; Akervall JA et al, 1997; XU J et al, 1998) 
have described the expression of Cyclin Dl in various subsites within the oral cavity 
adding that it was more often detected in sites such as tounge (Akervall JA et al, 
1997; Xu J et al, 1998), retromolar region (Xu J et al, 1998), palate (Lam KY et 
al, 2000), gingiva (Xu J et al, 1998) and floor of mouth (Lam KY et al, 2000) 
which has suggested that it might reflect epidemiological or racial differences in 
various populations. 
Oral Growth Suppressors and the Signal Transduction Pathway 
As oncogenes subvert pathways leading to growth promotion, inactivation of tumor 
suppressor genes cripples growth-inhibitory pathways. These events can occur at 
any level of the growth-inhibitory signal transduction pathway. Several extracellular 
ligands are oral keratinocyte growth inhibitors while TNF-a and transforming 
growth factor-beta (TGF-P) may provide important growth-inhibitory signals in oral 
epithelial cell biology. TNF-a alone and with interferon-7, has been demonstrated to 
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inhibit malignant oral keratinocyte proliferation (Aaronson, 1991; Howe et al, 1991; 
Sacchi et al, 1991). TGF-P is an inhibitor of keratinocyte proliferation whose 
activity is due, in part, to a known tumor suppressor gene, the retinoblastoma 
susceptibility gene (Rb) (Moses et al., 1990 Bookstein and Lee, 1991; Irish, 1992). 
Cell-surface molecules may also be important in inhibiting oral keratinocyte 
proliferation. E-cadherin, a cell-cell adhesion molecule associated with both 
invasion and metastasis, is downregulated in oral cancers (Frixen UH et al, 1991; 
Morton RA 1993; Mareel et al, 1994; Jiang et al, 1996; Hirohashi et al, 1998). 
Similarly P-cadherin expression was reduced in OSCC and it acts as an independent 
prognostic factor in patients with OSCC (Lo Muzio et al, 2004). Deleted in oral 
cancer (DCC) is a N-CAM like molecule believed to be an important cell-cell 
contact inhibitor that is mutated during oral cancer development (Kim et al, 1993). 
Growth suppressor intracellular messengers may include the adenomatous polyposis 
coli (APC) gene, a G-like protein frequently mutated in certain familial colorectal 
cancers (Groden et al, 1991). Recent evidence suggests that the APC gene may be 
altered in premalignant oral lesions {Largey et al, 1993). 
The transcription factor Rb, a known tumor suppressor gene, has been shown to 
have reduced expression in oral tumors (Kim et al, 1993). Alterations of Rb 
pathway components are frequent events in patients with epithelial dysplasia and 
predict clinical outcome in patients with squamous cell carcinoma (Soni R et al, 
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2005). Deregulation of both Rb and p53 pathways is associated with malignant 
transformation and adverse prognosis in oral tumorigenosis. It has been 
demonstrated that Rb pathway proteins are comparatively more important than p53 
pathway proteins for the prognostication of oral cancer patients (Jayasurya et al, 
2005). Expression of PRb2 /pl30 may be good prognostic indicator in patients with 
oral squamous cell carcinoma and also may be utilized for the sub classification of 
tumors with the Grade 3 mode of carcinoma invasion (Tanaka et al, 2001). 
Retinoic acid receptor-beta (RAR-P) is down regulated in head and neck cancers 
(Khuri et al, 1997). Retinoids are currently under investigation for prevention and 
reversion of oral premalignant lesions (DeLuca, 1991; Lotan et al, 1995; Ralhan R 
et al, 2006). 
Human chorionic Gonado-Tropin-p (hCGP), a glycoprotein hormone, is not 
expressed by normal or benign cells but is expressed in oral SCC (Acevedo HF, 
1995). Thus hCGP can be used as a marker of malignant transformation, and hCGp 
assays can serve as indicators of tumor progression (Regelsion W et al, 1995). 
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CHAPTER 3 MATERIALS AND METHODS 
The present study was conducted in the Department of Biochemistry, Jawaharlal 
Nehru Medical College, Aligarh Muslim University, Aligarh (JNMC,AMU,Aligarh) 
from Nov. 2004 to March 2007. Cases for the present study comprised of patients of 
oral cancer attending the OPD of Department of Otorhinolaryngology (ENT) or 
admitted to their wards of JNMC, Aligarh. Age and sex matched controls were 
recruited from healthy individuals. Prior consent was taken from all the cases as 
well as controls. 
The study comprised of total 250 human subjects with 100 patients and 150 
controls. Biopsy specimens were taken from 60 cases & 10 controls. Blood samples 
were collected from all the cases & controls. A thorough proper history with special 
emphasis on the tobacco & betel quid intake was taken. Patients having habit of 
smoking and/or alcohol intake were excluded from the present study. Complete 
clinical evaluation and relevant investigations were done in all the patient samples. 
This all information was recorded in the following pro forma: 
PRO FORMA 
S.No 
Name 
Age/Sex 
Education 
Occupation 
Marital Status 
Environment 
Complaints 
Date 
Ward/Bed No. 
OPD/CADS No. 
C/I 
Rural/Urban 
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Past History 
Treatment History 
Personal History 
Tobacco and betel quid intake 
Duration 
Site of lesion 
INVESTIGATION 
Routine 
Biopsy and histopathology 
Diagnosis 
Specific investigations 
Immunohistochemistry 
Agarose gel electrophoresis 
PCR-RFLP genotyping 
less than 6 months 
6-12 months 
12-18 months 
18-24 months 
Histopathology 
Post surgical specimens received included excisional and incisional oral biopsy 
specimens. They were processed by an automatic tissue processor (Histokinette). 
Embedding of the block was done as follows: 
a) Xylol with paraffin wax-one and half hour. 
b) Paraffin wax-one and half hour. 
Blocks were prepared in paraffin wax with the help of L-blocks. Sections were cut 
at 4-5 |im thickness with the help of rotatory microtome (SP-1120) and were 
subjected to following stains: 
a) Haematoxylin and Eosin 
b) Immunostaining 
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Staining Procedure 
Hematoxylin and Eosin methods: The following protocol was observed: 
1. Slides were dewaxed by application of heat and 1-2 min. in xylol. 
2. Hydration of sections done by graded alcohol (absolute alcohol, 80%, 70%, 
50%). 
3. Slides were washed in running tap water for 1-2 min. 
4. Dipped in filtered haematoxylin stain for lOmin. 
5. Washed in running tap water for 5-19 min. 
6. Decolonized using 1% acid alcohol to remove the excess stain. 
7. Rinsed in running water. 
8. Counter stained with eosin 1% for 2-4 min. 
9. Washed in running water to wash off excess stain. 
10. Dehydrated by dipping in 95% ethanol and absolute alcohol-15 dips in each. 
11. Cleared in xylol-15 dips. Mounted with DPX after drying. 
Result 
Cytoplasm of cells-pink 
Nucleus- blue 
Differentiation of tumors was analyzed according to the Broder's Classification as: 
1. Well differentiated (Grade I) - < 25% undifferentiated cells 
2. Moderately differentiated (Grade II) - <50% undifferentiated cells 
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3. Poorly differentiated (Grade III) - <75% undifferentiated ceils 
4. Anaplastic/pleomorphic (Grade IV) - >75% undifferentiated cells 
Methodology: 
Immunohistochemistry Procedure: 
• Positive Control: - Breast carcinoma (known to express p53 /cyclin Dl) 
• Preparation of sections: 
1. Formalin fixed, paraffin embedded sections were mounted on slides coated with 
poly-L-lysine solution. 
2. Sections mounted on coated slides were incubated at 56°C overnight for better 
adhesion. 
3. Sections were deparaffinized in xylol and hydrated through graded alcohols to 
Tris buffered saline (0.005 M TRIS buffer, pH7.6). 
4. Antigen retrieval was done using citrate buffer (0.01 mol/L, pH 6.0) in a pressure 
cooker by heating up to one whistle and then allowing to cool to room 
temperature before opening the lid of cooker. 
5. Endogenous peroxidase activity was blocked by treating sections with 3% 
hydrogen peroxide in methanol (LSAB Kit) for 10-15 minutes. 
IMMUNOSTAINING: 
1. Primary antibody (FL-393 and H-295 antibodies, Santa Cruz 
Biotechnology, USA for p53 and cyclinDl respectively) was added to the 
sections at room temperature and incubated overnight at SS^ C in a moist 
chamber. 
2. Sections were then washed with three changes of TBS for 10 minutes each. 
3. Sections were incubated in biotinylated secondary (Link) antibody at room 
temperature for 30 minutes in a moist chamber and washed in TBS(x3) for 10 
minutes duration each. 
4. Sections were incubated in streptavidin at room temperature for 45 minutes in a 
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moist chamber and washed in TBS. 
5. Sections were incubated in freshly prepared 3, 3' diaminobenzidine 
tetrahydrochloride (DAB) solution. This was prepared by diluting DAB 
chromogen (1 drop) in 1 ml of DAB substrate. 
6. Sections were washed in distilled water, counterstained in hemotoxylin (1-2 
dips), dehydrated through graded alcohols, cleaned in xylol and mounted in 
DPX. 
Results 
Positive staining was identified in the form of strong dark brown nuclear staining of the 
epithelial cells. 
Scoring of positive immunostaining 
For protein expression, only nuclear positivity (strong brown staining) was assessed 
quantitatively. Cells with only cytoplasmic staining were not counted. 
The quantification of protein positivity was done according to the method recommended 
by Hall and Lane (1994) and adopted by Chiang et al, (2000). Only the percentage was 
quantified and the percentage of positively stained cells in the whole layer of epithelium 
was determined by scanning the entire section and was recorded as follows: 
For Squamous cell carcinomas: 
= No epithelial cells stained 
+ (+1) = up to 25% of cells positive 
++(+2) = 26 to 50% of cells positive 
+++ (+3) = > 50% of ceils positive 
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Genomic DNA Isolation from Whole Blood 
For the present study, genomic DNA was isolated from 5ml of human whole blood 
samples, by Phenol-Chloroform method of DNA isolation. 
1. Human blood (5ml) was collected in vial containing anti-coagulant EDTA (Img/ml). 
2. Ice cold red cell lysis buffer ( 20ml, PH=7.6) was added to the blood sample in a 
falcon tube and kept on ice for 15 minutes with intermittent mixing several times to 
lyse RBCs. 
3. The lysate was centrifuged at 6000 rpm for 15 min at 4°C. 
4. The supernatant was discarded. 
5. Steps 2 to 4 were repeated until the white nuclear pellet was obtained. 
6. The pellet was suspended in 5 ml of lysis buffer (pH 8.0) buffer, followed by lOOul 
of proteinase K solution and 500nl of 10% SDS solution and incubated at 37 C on a 
shaker, overnight to lyse the nuclei. 
7. Equal volume of Tris equilibrated phenol (pH 7.5-8.0) was added, mixed well and 
centrifuged at 4000 rpm for 10 min at room temperature. 
8. The aqueous layer was transferred to another tube and equal volume of phenol: 
chloroform: isoamylalcohol (25:24:1) was added, mixed and centrifuged at 4000 
rpm for 10 min at room temperature. 
9. The aqueous layer was transferred to a fresh tube and equal volume of chloroform: 
isoamylalcohol (24:1) was added, mixed and centrifuged at 4000 rpm for 10 min at 
room temperature. 
10. DNA was precipitated by adding double the volume of ice cold absolute ethanol to 
the aqueous layer by gently mixing ,spin and pellet was washed with 70% ethanol, 
air dried and dissolved in double distilled water. 
Agarose Gel Electrophoresis 
The isolated DNA samples were quantified by agarose gel electrophoresis using 0.8% 
concentration of agarose in 0.5x TBE (Tris borate EDTA). Agarose (3% in 0.5x TBE) 
was used for determination and identification of PCR products, after genomic DNA 
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samples were assayed by polymerase chain reaction. The location of DNA within the gel 
can be determined directly by staining with low concentrations of fluorescent 
intercalating dyes, such as Ethidium bromide. Agarose gels have a greater range of 
separation. DNA's from 50 bp to several megabases in length can be separated on 
agarose gels of various concentrations and configurations. Small DNA fragments (50-
20,000 bp) are best resolved in agarose gels run in a horizontal configuration in an 
electric field of constant strength and direction. Under these conditions, the velocity of 
the DNA fragments decreases as their length increases and is proportional to electric field 
strength. The agarose gels casted with low concentration of agarose are capable of 
resolving extremely large DNA molecules. 
Preparation of Gel 
Prior to the preparation of agarose gel, appropriate combs were set into the gel plate 
according to the requirement of wells. 
1. The solution was boiled, preferably in a microwave oven. 
2. Then the solution was cooled down to 50°C. 
3. Ethidium bromide (0.5 mg/ml) was added to the agarose solution, mixed and then 
poured into the gel plate. 
4. When the gel was polymerized, combs were removed. 
5. The gel was placed in the running apparatus filled with 0.5x TBE. 
Preparation of samples to be loaded 
The appropriate amount of each sample was transferred to a microfuge tube and mixed 
with loading buffer to give final Ix strength. 
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Loading of samples into the wells: 
1. The DNA samples or the PCR products were loaded into the wells using 
micropipette. 
2. The electrophoresis chamber was closed with a lid and current was applied (5V/cm). 
3. The bromophenol blue dye in the DNA samples acts as a "front wave" that runs faster 
than the DNA itself. When the "front wave" approached the end of the gel (app 3/4th 
of the gel), electrophoresis was terminated. 
4. The DNA or PCR product was visualized in a UV transilluminator. 
PCR-RFLP Genotyping 
Polymerase chain reaction is a molecular biology technique which allows a small amount 
of the DNA molecule to be amplified exponentially. PCR is an iterative process 
consisting of three elements: denaturation of the template by heat (temperature, 94-96°C), 
annealing of the oligonucleotide primers to the single stranded target sequence(s), the 
temperature of this stage depends on the primers and is usually 5°C below their melting 
temperature (45-60°C), and extension of the annealed primers by a thermostable 
DNApolymerase, (Taq polymerase), this step takes 1 minute per thousand base pairs. In 
PCR-RFLP, PCR products are subjected to restriction digestion overnight at 37°C, the 
digestion products are resolved on agarose gel and bands are visualized. 
hOGGI Genotyping 
hOGGI genotyping was performed using a PCR-RFLP technique. The primers used to 
identify the polymorphism at codon 326 of hOGGI were adopted from those published in 
literature (Table 3.1). A 40-\il reaction mixture containing 29.71 [xl of double-distilled 
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water, 4nl of lOxPCR buffer , 1 |A1 of each primer (5 mM/nl), 1 nl of the mixture of 
deoxynucleoside triphosphates (2.5 mM/ nO, 1.2 i^l of MgCl2 (50 mM/ ill), and 0.45 unit 
of (5 unit/ jil) Taq DNA polymerase (Amersham Pharmacia Biotech) was used. The PCR 
condition was initiated by a 4 min denaturation step at 94°C, followed by 35 cycles at 94^^ 
C for 40 s, 55°C for 30 s, 72°C for 2 min. and a final step at 72''c for 10 minutes. The 
PCR products were subjected to restriction digestion overnight at 37°C by Fnu4HI. The 
digestion products were resolved on 3% agarose gel. 
XRCCI Genotyping 
XRCCI genotyping was performed using a PCR-RFLP technique. The primers used to 
identify the polymorphism at codon 280 of XRCCI were adopted from those published in 
literature (Table 3.1). A 40- pi reaction mixture containing 29.71 nl of double-distilled 
water, lOxPCR buffer (4 |il), 1 |A1 of each primer (5 mM/ i^ l), 1 |il of the mixture of 
deoxynucleoside triphosphates (2.5 mM/ |il), 1.2 nl of MgCb (50 mM/ \i\), and 0.45 unit 
of (5 unit/ \x\) Taq DNA polymerase (Amersham pharmacia Biotech) was used. The PCR 
condition was initiated by a 4- min denaturation step at 94" C, followed by 35 cycles at 
94V for 40 s, 55''C for 30 s, 72°C for 2 min. and a final step at 72° C for 10 min. The 
PCR products were subjected to restriction digestion overnight at 3 7 ^ by Rsal. The 
digestion products were resolved on 3.0% agarose gel. 
CYP2E1 Genotyping 
The RFLPs in the 5' flanking region and in intron 6 of the CYP2E1 gene were determined 
by PCR amplification followed by digestion with Rsal and Dral restriction enzymes 
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respectively. The primers used to identify the polymorphism at Rsal and Dral sites of 
CYP2E1 were adopted from those published in literature (Table 3.1). Briefly, a 40- 1^ 
reaction mixture containing 29.71 \i\ of double-distilled water, lOx PCR buffer (4nl), 1 1^ 
of each primer(5 mM/^l),l}il of the mixture of deoxynucleoside triphosphates (2.5 mM/ 
nO, 1.2 \i\ of MgCb (50 mM/ ^1), and 0.45 unit of (5 unit/ nl),TaqDNA polymerase 
(Amersham Pharmacia Biotech) was used. The PCR condition was initiated by a 4-min 
denaturation step at 94°C, followed by 35 cycles at 94°C for 40 s, 55^0 for 30 s, 72° C for 
2 min. and final step at 72''C for 10 min. The PCR products were subjected to restriction 
digestion overnight at 37°C by Rsal and Dral (New England Biolabs, Inc., Beveraly, MA) 
respectively. The digestion products were resolved on 3.0% agarose gels. 
Table 3.1: Primer Sequences used in the PCR-RFLP of hOGGI, XRCCl, CYP2E1 Rsal 
and Dral genotyping 
Target 
CYP2E1 
CYP2E1 
GRXRCCl 
GRhOGGl 
F-Rsa 
R-Rsa 
F-Dra 
R-Dra 
F-280 
R-280 
F-326 
R-326 
Primer sequence (5'-
3') 
ccagtcgagtctacattgtca 
Ttcattctgtcttctaactgg 
tcgtcagttcctgaaagcagg 
gagctctgatgcaagtatcgca 
ttgacccccagtggtgct 
Ccctgaaggatcttccccagc 
actgtcactagtctcaccag 
ggaaggtgcttggggaat 
Approximate size (bp) 
410 
995 
188 
200 
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statistical Analysis 
An SPSS for windows computer programme (SPSS Inc. Chicago 11, USA, version 13) 
was used for statistical analysis. The association between protein expression and tumor 
location was analyzed by the Chi-square test. The relationship between protein 
expression and histolopathological grade was analyzed by Kruskal-Wallis analysis of 
variance (ANOVA) .Wilcoxon paired sample test was used to analyze the differences 
within the three categories of histopathological grade and protein expression. 
The chi-square test for heterogenity was used for categorical variables to test the 
hypothesis that the distribution of allele prevalance was same for the cases and controls. 
Conditional logistic regression technique was used to examine association of 
polymorphisms with risk of oral cancer. 
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CHAPTER 4 OBSERVATIONS 
In the present case control study, risk of oral cancer has been estimated in the 
tobacco and betel quid chewers. Total 250 human subjects with 100 patients and 150 
controls, who attended the ENT O.P.D. or were admitted in their ward in J.N. 
Medical College Hospital, A.M.U., Aligarh from Nov, 2004 up to May, 2007 were 
included in the study. 
Age Incidence 
In the present series, patients belonged to age group of 25-100 years, out of which 
maximum incidence of cases(n=62) was seen between 50-75 years of age group 
(62% of cases). Only 20% (n=20) and 18% (n=18) cases were in the age group of 
25-50 years and 75-100 years respectively (Table 4.1). In controls, 50-75 age group 
predominated with 60% (n=90) of the controls belonging to this age group. Only 
6.66% (n=10), 18% (n=27) and 15.33 % (n=23) controls were in the age group of 0-
25, 25-50 and 75-100 age groups respectively. 
Table 4.1: Occurrence of oral cancer in different age group of patients 
CATEGORY 
Age Group (in yrs.) 
0-25 
25-50 
50-75 
75-100 
Total 
Male 
0 
13 
48 
14 
75 
CASES 
Female 
0 
07 
14 
04 
25 
Total 
0 
20 
62 
18 
100 
CONTROLS 
Male 
7 
21 
68 
19 
125 
Female 
3 
6 
22 
04 
35 
Total 
10 
27 
90 
23 
150 
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Sex Incidence 
Out of the total 100 cases studied, 75 cases (75%) were males and rest (25%) were 
female, male-female ratio being 3:1 (Table II). Out of 150 controls, 115 (76.66%) 
were males and rest 35 (23.33%) were females, male: female ratio being 3.28:1. 
Table 4.2. 
Table 4.2: Number and percentage of patients in different sex groups 
Category 
Sex 
Male 
Female 
Total 
Cases 
Number 
75 
25 
100 
Percentage 
75% 
25% 
100% 
Controls 
Number 
115 
35 
150 
Percentage 
76.6% 
23.33% 
100% 
Mean age of male and female cases were 58 years and 53 years respectively and 
average age of cases was 56.75 years (Table 4.3). Mean age of male and female 
controls was 56 years and 54 years respectively and average age of controls was 
55.53 years. 
Table 4.3: Mean age of patient in different sex groups 
Category 
Sex 
Male 
Female 
Total 
Cases 
Number 
75 
25 
100 
Mean age 
58 
53 
56.75 
Controls 
Number 
115 
35 
150 
Mean age 
56 
54 
55.53 
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Duration of Symptoms 
Most of cases (68.97%) presented with some complaint within first 6 months of the 
start of the lesion. Only 23.72% presented after 6 months to 1 year while 5.83% and 
1.45% presented symptoms after 12 months and 18 months respectively (Table 4.4). 
Table 4.4: Duration of initial presentation of clinical symptoms by patients 
^^~~~—-__^I)uration (in months) 
~~~-~-~..__^^ 
Presenting Complaint ~^"~~~~--~~-,__^  
Difficulty in swallowing 
Burning in mouth & throat 
Pain during swallowing 
Swelling in neck 
Change in voice 
Pain in the lesion 
Pain in the ear 
Difficulty in opening the mouth 
Difficulty in speech 
Bleeding from the mouth 
Increased salivation 
Total 
Percentage 
<6 
55 
35 
15 
13 
06 
36 
06 
07 
03 
06 
07 
189 
68.97% 
6-12 
14 
08 
14 
07 
03 
11 
04 
-
01 
01 
02 
65 
23.72% 
12-18 
10 
-
-
-
01 
02 
02 
-
-
-
01 
16 
5.83% 
18-24 
01 
02 
-
-
-
01 
-
-
-
-
-
04 
1.45% 
Symptoms of Patients 
Most of the patients presented with multiple symptoms with difficulty in swallowing 
being the most common symptom (80 cases). Pain in the lesion (50 cases), burning 
in the mouth and throat(45 cases) and pain during swallowing(29 cases) were the 
next common symptoms. Other complaints were less common as shown in table 4.5. 
^ H 
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Table 4.5: Number of cases showing occurrence of different symptoms 
S. No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
Presenting Complaint 
Difficulty in swallowing 
Pain in the lesion 
Burning in mouth & throat 
Pain during swallowing 
Swelling in neck 
Pain in the ear 
Change in voice 
Increased salivation 
Difficulty in opening the mouth 
Bleeding from the mouth 
Difficulty in speech 
No. of cases 
80 
50 
45 
29 
20 
12 
10 
10 
07 
07 
04 
Relation of Tobacco and Betel Quid Chewing with Oral Cancer 
Out of 100 cases studied, all 100 (100%) had used tobacco & betel quid. Thirty 
eight controls (out of 150) had used tobacco and betel quid (Table 4.6). 
Table 4.6: Chi square values of tobacco and betel quid in oral cancer in patients and 
controls 
""""•^ ---......^ ^^  Disease 
Risk factor —..^ 
Tobacco & betel quid 
(Exposed) 
Non-users 
(Not exposed) 
Total 
Oral Cancer present 
(cases) 
100 
(a) 
0 
(c) 
100 
(a+c) 
Oral Cancer 
absent 
(Controls) 
38 
(b) 
112 
(d) 
150 
(b+d) 
Total 
138 
(a+b) 
112 
(c+d) 
250 
(1) Exposure Rates: 
Cases = a/(a+c) 
Controls = b/ (b+d) 
100/100 
38/150 
100% 
25.3% 
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This shows that the consumption of tobacco and betel quid is highly related with the 
development of oral cancer as exposure rate among cases is very high i.e. 100% in 
comparison to the low exposure rate of 25.3% among controls. However this cause-
effect relationship is examined more scientifically on the basis of various other 
statistical tests like Chi-square test (x test). 
Chi square test offers an opportunity of testing the significance of difference 
between two proportions. This test is based on the "Null Hypothesis" viz. there is no 
difference between tobacco and betel quid users and non-users in the development 
of oral cancer. We shall now rewrite the previous table showing the observed (O) 
and expected (E) values in each cell (Table 4.7). 
Table 4.7: Exposure of tobacco and betel quid in oral cancer patients and controls 
to calculate x^  value 
^ ^ ~~-._.,.^ ^^  Disease 
Risk factor -^~—.^  
Tobacco and betel quid chewers 
Non-users 
Total 
Oral Cancer 
Present 
0=100 
E= 69 
0=0 
E=56 
125 
Oral Cancer 
Absent 
0=38 
E=69 
0=112 
E=56 
125 
Total 
138 
112 
250 
X^  = E (O-E)VE=135.226 
The calculated value of x^  is 135.226 while the value ofp (Probability) at 95% level 
of significance for 1 degree of freedom (d.f.) is .000. 
It means that p<0.001 so it is "Statistically significant". It indicates that our "Null 
hypothesis" was wrong and there is definite cause-effect relationship or we can say 
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that there is strong association between consumption of tobacco and betel quid with 
development of oral cancer. 
Socio Economic Status and Oral Hygiene 
The role of these factors in the predisposition of patients to the development of oral 
cancer was not studied. However it was noted that most of the sufferers belonged to 
the lower socio-economic status and oral hygiene was poor in most of the patients. 
Site of Lesion 
Oral cancer most commonly occurred in buccal mucosa in cases. The incidence of 
oral cancer in different sites of oral cavity is given below (Table 4.8). 
Table 4.8: The incidence of oral cancer in different sites of oral cavity 
S. No. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
Site of Lesion 
Tongue 
Buccal mucosa 
Lip 
Hard palate 
Floor of mouth 
Gingivia 
Retromolar region 
No. of Cases 
22 
45 
06 
05 
17 
03 
02 
Percentage 
22% 
45% 
06% 
05% 
17% 
03% 
02% 
Oral cancer most commonly involved buccal mucosa and occurred in 45 cases 
(45%). Next commonly it involved tongue (22%) and floor of mouth (17%) 
respectively. Other sites are less commonly involved. 
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Histological Type of Lesion 
All the biopsy samples of the patients were found to be having squamous eel 
carcinoma on histopathological examination (Table 4.9). 
Table 4.9: Distribution of oral cancer lesion in different histological types 
Histological type 
Squamous cell carcinoma 
Adenocarcinoma 
Lymphoepithelioma 
No. of cases 
60 
0 
0 
Percentage 
100 
0 
0 
Immunohistochemical Studies 
p53 Protein Expression 
Tissues of oral SCC patients with tobacco and betel quid chewing habit (60 
specimens) and 10 normal oral tissues were subjected to immunohistochemical 
staining for expression of p53 using FL-393 antibody (Santa Cruz Biotechnology, 
USA). Only strong brown nuclear staining of epithelial cells was considered 
positive. Those histological sections with uniform and good intensity were assessed 
for p53 scoring. The scores obtained were expressed as: 
Positive cases (%)^ the percentage of cases showing positive staining with 
IHC. 
p53 positivity (%)-> the percentage of cells showing a positive staining-i;eaction 
with P53 IHC. 
p53 was expressed in 65% (n=39) of the cases but was not expressed in controls. 
Figure 1 (A-D) shows the expression of p53 in tobacco and betel quid chewers as 
well as in controls. There were 34(56.6%) cases of well differentiated SCC, 
CHAPTER 4: OBSERVATIONS 78 
^ * ' • " • . . • ' - " • - • • 
' ^ J -
^"•:-/ 
".W--. , V-V.»r-'. 
• • • " ' * " , • ; • • • • . ' " ' 
Representative Figu 
',«• 
'/ 
:. 
• ... i ,. 
^, 
. 
yi '^ 
u<R( a jSuSn **' 
, • **^ ,.." 
r:*'*. f',4''"A- 4-"*'." 
re Showing Expression of 
pS3 in Normal Tissue 
Representative Figure Showing Expression of 
pS3 in IVIoderately Differentiated Oral SCC 
• 
% • 
t 
• 
# • 
Representative Figure Showing Expression of 
pS3 in Well Differentiated Oral SCC 
• « f > 
Representative Figure Showing Expression of 
pS3 in Pooriy Differentiated Oral SCC 
Figure 1 (A - D): Immunohistochemical detection of p53 using p53 antibody in 
tissues obtained from oral cancer patients 
CHAPTER 4: OBSERVATIONS 79 
18(30%) cases of moderately differentiated SCC and 8(13.3%) cases of poorly 
differentiate SCC. Table 4.10 depicts the positive cases (%) and mean p53 positivity 
(%) in oral SCC patients and controls along with their sub categories. 
Table 4.10: p53 Expression in oral SCC's in tobacco and betel quid chewers 
Histological Diagnosis 
Category 
Oral SCC 
a)Well differentiated 
b)Moderately differentiated 
c)Poorly differentiated 
Controls 
Total 
Cases 
60 
34 
18 
08 
10 
p53 Expression 
Positive cases 
(%) 
39(65%) 
20(58.8%) 
13(72.22%) 
06(75%) 
0 
Negative cases 
(%) 
21(35%) 
14(41.2%) 
05(27.77%) 
02(25%) 
10 
Positivity 
Mean + SD 
26.46 ±23.90 
20.0+19.32 
29.33+23.50 
47.5+31.38 
0 
Range 
0-75 
0-55 
0-70 
0-75 
0 
It was found that there was no detectable level of p53 expression in controls (Figure 
lA) while in oral SCC patients with tobacco and betel quid chewing habit, the 
percentage of positive cases as well as p53 positivity showed an increase with 
elevated grade of SCC (Figure 2). 
It was found that expression of p53 was significantly associated with histological 
grade in oral cancer in tobacco and betel quid chewers (x^=7.077, df=2, p=0.029). 
Statistically significant difference in p53 positivity was observed on comparing well 
differentiated SCC (p53 positivity= 20+19.32) with poorly differentiated SCC (p53 
positivity=47.5+31.38, p=0.001) but no statistical significance (p=0.27) was 
observed in p53 positivity between poorly differentiated SCC (p53 positivity= 
47.5+31.38) and moderately differentiated SCC (p53 positivity= 29.33+23.50), as 
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Figure 2: Expression of p53 in oral SCC's in tobacco and betel quid chewers 
well as between well differentiated SCC (p53 positivity= 20+19.32) with 
moderately differentiated SCC (p53 positivity=29.33±23.50, p value =0.27). 
Expression of p53 in various sites of oral cavity was investigated and it was found 
that p53 was more frequently expressed in sites like gingivia (-,100%), floor of 
5 20 7 1 
mouth (-,71%) buccal mucosa (—,64.5%) tongue (—,70%) and lip (-,60%) 
7 31 10 5 
while less frequently in sites like hard palate (2/4,50%) and retromolar region 
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(—,50%). Further the association between expression of p53 and site of incidence 
of oral cancer was evaluated. It was found that there is no significant association 
between p53 expression and primary site of incidence of oral cancer (x =1.427, 
df=6, p=0.964) 
Cyclin Dl Expression 
Tissues of oral SCC patients with tobacco and betel quid chewing habit (60 
specimens) and 10 normal oral tissues were subjected to immunohistochemical 
staining for expression of Cyclin Dl using H-295 antibody (Santa Cruz 
biotechnology, USA). The strong brown nuclear staining of epithelial cells was 
considered positive. Those histological sections with uniform and good intensity 
were assessed for Cyclin Dl scoring. The scores obtained were expressed as: 
• Positive cases (%)^ the percentage of cases showing positive staining with 
IHC. 
• Cyclin Dl positivity (%)-> the percentage of cells showing a positive staining 
reaction with Cyclin Dl IHC. 
Cyclin Dl was expressed in 58.33% (n=35) of the cases but was not expressed in 
controls. Figure 3 (A-D) shows the expression of Cyclin Dl in tobacco and betel 
quid chewers as well as controls. There were 34(56.6%) cases of differentiated SCC, 
18(30%) cases of moderately differentiated SCC and 8(13.3%) cases of poorly 
differentiated SCC. Table 4.11 depicts the positive cases (%) and mean Cyclin Dl 
positivity (%) in OSCC patients and controls along with their sub categories. 
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Representative Figure Showing Expression of 
Cyclin Dl in Normal Tissue 
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Figure 3 (A - D): Immunohistochemical detection of Cyclin Dl using Cyclin Dl 
antibody in tissues obtained from oral cancer patients 
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Table 4,11: Cyclin Dl Expression in Oral SCC's in tobacco and betel quid chewers 
Histological 
Diagnosis 
Category 
Oral s e c 
a)Well differentiated 
b)Moderately differentiated 
c)Poorly differentiated 
Control 
Total 
Cases 
60 
34 
18 
08 
10 
Cyclin Dl Expression 
Positive cases 
(%) 
35(58.33%) 
18(52.94%) 
11(61.1%) 
06(75.0%) 
0 
Negative cases 
(%) 
25(41.6%) 
16(47.05%) 
07(38.88%) 
02(25%) 
10 
Positivity 
Mean ± SD 
22.16±22.18 
16.61±17.89 
24.38±21.93 
37.0±32.51 
0 
Range 
0-75 
0-51 
0-70 
0-74 
0 
As revealed by immunohistochemistry, there was no cyclin Dl expression in 
controls (Figure 3A) while in oral SCC patients with tobacco and betel quid 
chewing habit, the percentage of positive cases as well as cyclin Dl positivity 
showed an increase with high grade of SCC (Figure 4). 
80 
70 
60 
SO 
40 
30 
20 
10 
• P(MilMly(%) 
TOTAL OSCC WDSCC MDSCC PDSCC 
Figure 4: Expression of Cyclin Dl in oral SCC's in tobacco and betel quid chewers 
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It was found that there is no statistically significant association between Cyclin Dl 
expression and histological grade in oral cancer in tobacco and betel quid chewers 
(X =3.954, df=2, p=0.138). However statistically significant difference (p=.002) 
was observed in Cyclin Dl positivity between well differentiated SCC (Cyclin Dl 
positivity=16.61±17.89) and moderately differentiated SCC (Cyclin Dl positivity= 
24.38+21.93) as well as between well differentiated SCC (Cyclin Dl 
positivity= 16.61 ±17.89) and poorly differentiated SCC (Cyclin Dl 
positivity=37.0±32.51), p=.043. Similarly, statistically significant difference was 
observed between moderately differentiated SCC (Cyclin Dl positivity= 
24.38+21.93) and poorly differentiated SCC (Cyclin Dl positivity=37.0±32.5]), p 
value=0.043. 
Expression of Cyclin Dl in various sites of oral cavity was investigated and it was 
found that Cyclin Dl was more frequently expressed in sites like hard palate 
3 "l 
—,75% , buccal mucosa 
4 / 
21^  
31 
,67% I and lip -,60% and less frequently in gingivia 
v5 ) 
°,00/. , tongue 
f 4 
— ,40% I and floor of mouth 
lio 
4 
- , 4 3 % 
7 
The association between expression of Cyclin Dl and sites of incidence of oral 
cancer was also evaluated in our study. It was found that there is no significant 
association between Cyclin Dl expression and primary site of incidence of oral 
cancer (;f-=5.122, df=6, p=0.528). 
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Genetic Susceptibility 
Blood was collected in EDTA vials from 100 patients of oral cancer with tobacco and 
betel quid chewing habit and 150 age and gender matched healthy controls were recruited 
for the study and used for isolation of DNA. 
Genomic DNA was subjected to the agarose gel electrophoresis for assaying its quality 
and quantity. Figure 5 shows a representative agarose gel of the genomic DNA isolated 
from patients with tobacco and betel quid chewing habit and healthy controls. 
XRCCI Genotyping 
PCR-RFLP based analysis of XRCCI codon 280 gene polymorphism was carried out by 
the method of Cho et al, 2003. The polymorphism results in mutation from A to G in 
exon I at codon 280 which resulted in the replacement of Arginine by Histidine. The PCR 
products were subjected to restriction digestion overnight at 37°C by Rsal. The PCR 
products were resolved on 3.0% agarose gel. Two bands at 126 and 62 bp characterized 
the wild type Arg allele for codon 280 while a single band at 188 bp characterized the 
variant type His allele and heterozygotes (Arg/His) showed all the three bands (Figure 6). 
The distribution of XRCCI codon 280 genotype frequencies in oral cancer patients and 
age and gender matched healthy controls is summarized in Table 4.12. 
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Figure 5: RepresentativeGd of DNA Isolated from oral carx»r patients 
Integrity of DNA isolated from the specimens was analysed by 0.8% agarose gel 
electrophoresia In this figure lanes representing are DNA samples isolated from b)lood of 
healthy controls& patients having oral cancer. 
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Figure 6: Representative Gel of PCR-RFLP analysis ofX/?CC7/280 codon in oral cancer 
patients 
RFLPs of PCR-amplified fragments obtained using Rsal and subjected to Polyacrylamide 
gel electrophoresis. Kl, homozygote variant His allele at codon 280; k2, k3, k4, k5, k6, 
k7, k9, klO, kl 1, kl3,kl4, kl6, kl7, kl8„ homozygote wild type Arg allele at codon 280; 
kl5, heterozygote. A single band at 188 bp characterizes the variant type His allele at 
codon 280; two bands at 126 and 62 bp characterize the wild type Arg allele for codon 
280. DNA was isolated from blood as described in materials and methods. 
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Table 4.12: Distribution of XRCCI codon 280 genotypes in oral cancer patients 
XRCCI 
Genotypes 
Arg/Arg 
Arg/His 
His/His 
Healthy Controls 
(N%) 
116(77.33%) 
32(21.33%) 
02(1.33%) 
Oral Cancer Patients 
(N%) 
62(63%) 
33(33%) 
04(4%) 
p value 
.015 
Odds Ratio 
1.63(95 
CI=1.1-
2.413) 
The XRCCI (Arg/His) genotype was observed in 33% of patients as compared to 21.33% 
in controls, and XRCCI (His/His) genotype was observed in 4% of patients as compared 
to 1.33% in controls. 
XRCCI Arg^ °^His Polymorphism was found to be associated significantly with risk of 
oral cancer in tobacco and betel quid chewers (p=.015 ).The individuals with variant 
genotypes (Arg/His or His/His) were at increased risk of oral cancer ( 0R= 1.63, 95% 
CI= 1.1-2.413) as compared to individuals having wild type homozygous genotype 
(Arg/Arg).Thus it can be concluded that XRCCI (Arg/His , His/His) genotypes are 
closely related with high risk of development of oral cancer in tobacco and betel quid 
chewers. 
hOGGl Genotyping 
hOGGl codon326 gene polymorphism was carried out by the method of Le Marchand et 
al, 2002.The polymorphic mutation at codon 326 results in the replacement of Serine by 
Cysteine. The PCR products were subjected to restriction digestion overnight at 37''C by 
fhu4Hl. The digestion products were resolved on 3% agarose gel. A single band at 200bp 
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characterized the wild type Serine allele at codon 326 while a band at 100 bp 
characterized the variant Cysteine allele while heteozygotes (Cys/Ser) show both the 
bands (Figure 7). The distribution of hOGGl genotype frequencies in oral cancer patients 
and age and gender matched healthy controls is summarized in table 4.13. 
Table 4.13: Distribution of hOGGl codon 326 genotypes in oral cancer patient's oral 
cancer 
Genotype 
Ser/Ser (Wild type) 
Cys/Ser 
Cys/Cys (Variant) 
Healthy Controls 
N (%) 
125(83.33%) 
22 (14.66%) 
03 (2%) 
Oral cancer patients 
N (%) 
61(61%) 
32(32%) 
07(7%) 
p-value 
.000 
Odds ratio 
(OR) 
2.3(95% 
CI=1.5-3.61) 
The hOGGl (Ser/Cys) genotype was observed in 32% of patients as compared to 
14.66%! in controls, and hOGGl (Cys/Cys) genotype was observed in 7% of patients as 
compared to 2% in controls. 
hOGGl Ser^ '^ ^Cys polymorphism was found to be significantly associated with the risk of 
oral cancer in tobacco and betel quid chewers (p=.000). The individuals with the variant 
genotype ( Cys/Cys or Ser/Cys) were at increased risk of oral cancer as compared to 
individuals having wild type genotype (0R= 2.3, 95%)C1= 1.5-3.61). The data of present 
study suggest that hOGGl (Ser/Cys) and (Cys/Cys) genotypes are closely related with 
high risk of development of oral cancer in tobacco and betel quid chewers. 
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Figure 7: Representative Gel of PCR-RFLP analysis of hOGGl/326 codon in oral cancer 
patients 
RFLPs of PCR-amplified fragments obtained using Fnu4H\ and subjected to 
Polyacrylamide gel electrophoresis. UD, undigested; M, marker. K13, K15, K18, K20, 
K21, K24, K27, homzygote wild type Ser allele at codon 326; Kll, K12, K14, K16, KIT, 
K19, K22, K23, K25, K26, K28, heterozygote Cys variant at codon 326;. A single band 
at 200 bp characterizes the wild type Ser allele at codon 326; a band at 100 bp 
characterizes the variant Cys allele. DNA was isolated from blood as described in 
materials and methods. 
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CYP2E1 Genotyping 
PCR-RFLP based analysis of CYP2E1 gene polymorphism was carried out by following 
method of Wen Tan et ai, (2000) and Kato et al, (1994) for Rsa 1 and Oral 
polymorphisms respectively. The RFLP in the 5' flanking region and in intron 6 of the 
CYP2E1 gene were determined by PCR amplification followed by digestion with Rsal 
and Dral respectively. Rsal specific primers produced a 410 bp product. Rsal digestion 
produced three CYP2E1 genotypes, i.e., the predominant homozygote A/A, the 
heterozygote A/C, and the rare homozygote C/C. The predominant allele (A) was 
sensitive to Rsal digestion and resulted in two fragments at 360 and 50 bp, whereas the C 
allele was resistant to Rsal digestion and heterozygotes (A/C) show all the three bands.So 
variant homozygote individuals have a single 410 bp band (C allele homozygous,C/C) 
where as Rsal-site homozygotes have a smaller sized band (360 bp) in case 50 bp 
fragment has run out (homozygous type A/A genotype). Heterozygous cases should have 
two bands 410 bp and 360 bp after a 50-bp fragment has run out (genotype A/C) (Figure 
8). The distribution of CYP2EI Rsal genotype frequencies in oral cancer patients and age 
and gender matched healthy controls is summarized in Table 4.14. 
Table 4.14: Distribution of CYP2EI Rsal genotypes in oral cancer patients 
Genotype 
A/A (Wild type) 
A/C variant 
C/C (variant type) 
Healthy Controls 
N (%) 
120(80%) 
27(18%) 
03(2%) 
Oral cancer patients 
N (%) 
60(60%) 
34(34%) 
06(6%) 
p-value 
.001 
Odds ratio 
(OR) 
2.0 
(95C1 = 1.3-
2.9) 
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Figure 8: Representative Gel of PCR-RFLP analysis of CYP2E1/Rsal in oral cancer 
patients 
RFLPs of PCR-amplified fragments obtained usiftg Rsal, and subjected to Agarose gel 
electrophoresis. k8 and k9 hetrozygote A/C allele; k5 homozygote C/C allele; k2, k3, 
k6,k7 homozygote A/A allele. Variant homozygote individuals have a single 410 bp band 
(C allele homozygous,C/C) where as Rsal-site homozygotes have a smaller sized band 
(360 bp) in case 50 bp fragment has run out (homozygous type A/A genotype). DNA was 
isolated from blood as described in materials and methods. DNA was isolated from blood 
as described in materials and methods. 
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The occurrence of CYP2E1 (A/C) genotype was observed in 34% of patients as 
compared to 18% in controls and CYP2E1 (C/C) genotype was observed in 6% of 
patients as compared to 2% in controls. 
CYP2ElRsal polymorphism was found to be significantly associated with the risk of oral 
cancer in tobacco and betel quid chewers (p=0.001). The individuals with the variant 
genotype (A/C or C/C) were at increased risk of oral cancer as compared to individuals 
having wild type genotype (0R= 2.0, 95% Cl= 1.3-2.9). It can be concluded that 
CYP2E1 (A/C) and (C/C) genotypes are closely related with high risk of development of 
oral cancer in tobacco and betel quid chewers. In CYP2E1 Dral polymorphism, Dral 
specific primers produced 995 bp product. Dral digestion produced three CYP2E1 
genotypes: (a) the predominant homozygote, DD; (b) the heterozygote, CD; and (c) the 
rare homozygote, CC. Dral site yielded 3 fragments of 572-, 302-, and 121- bp (D allele 
homozygous, D/D) while its absence yielded 874- bp band and 121- bp band (C allele 
homozygous, C/C) while heterozygotes (D/C) showed 874-, 572-, 302-, and 121-bp 
bands (Figure 9).The distribution of CYP2E1 Dral genotype frequencies in oral cancer 
patients and age and gender matched healthy controls is summarized in Table 4.15. 
Table 4.15: Distribution of CYP2E1 Dral genotypes in patients 
Genotype 
D/D(Wild type) 
C/D 
C/C (variant) 
Healthy Controls 
N (%) 
102(68%) 
47(31.33%) 
01(0.66%) 
Oral cancer patients 
N (%) 
56(56%) 
39(39%) 
03(3%) 
P-
value 
.049 
Odds ratio 
(OR) 
1.37(0.9-
1.89) 
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The CYP2E1 (C/D) genotype was observed in 39% of patients as compared to 31.33% in 
controls and CYP2E1 (C/C) genotype was observed in 3% of patients as compared to 
0.66% in controls. CYP2E1 Dral polymorphism was found to be significantly associated 
with the risk of oral cancer in tobacco and betel quid chewers (p=.049). The individuals 
with the variant genotype (C/D or C/C) were at increased risk of oral cancer as compared 
to individuals having wild type genotype (0R= 1.37, 95% Cl= 0.9-1.89). Thus, it can be 
concluded that CYP2E1 (C/D) and (C/C) genotypes are closely related with high risk of 
development of oral cancer in tobacco and betel quid chewers. 
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Figure 9: Representative Gel of PCR-RFLP analysis of CYP2E1/Dral in oral cancer 
patients 
RFLPs of PCR-amplified fragments obtained using Dral and subjected to Agarose 
gel electrophoresis, kl, k6, k2 homozygote DD genotype; k3 homozygote CC 
genotype; k4, k5 heterozygote CD allele. Dral site yielded 3 fragments of 572-,302-, 
and 121- bp (D allele homozygous, D/D) while its absence yielded 874- bp band and 121-
bp band (C allele homozygous, C/C) .DNA was isolated from blood as described in 
materials and methods. 
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CHAPTER 5 DISCUSSION 
Oral cavity cancer is one of the commonest cancers in India and other South Asian 
countries (Park, 2005). It is a major cause of cancer morbidity and mortality, and its 
poor prognosis ensues in full blown cancer (Pindborg, 1977; Saranath, 2000). 
Therefore an improvement in prevention and control is of critical importance. 
Researchers agree that the early diagnosis of oral carcinoma greatly increases the 
probability of cure with minimum impairment and deformity. In this regard, 
detection of mutations in tumor suppressor genes or oncogenes and interindividual 
variability in sensitivity to the carcinogens might facilitate identification of 
individuals who are at a high risk of developing cancer. 
Keeping this in view, the purpose of the present study was to evaluate the 
expression of p53 (tumor suppressor gene) and Cyclin Dl (cell Cycle regulator 
gene) as well as association of DNA repair genes (hOGGI Ser^^^Cys, XRCCI 
Arg^^^His) and drug metabolizing gene (CYP2E1 Rsal and Dral) polymorphisms 
with risk of oral cancer in tobacco and betel quid chewers of northern India. 
The present study included 100 patients and 150 healthy subjects as controls. 
Biopsy specimens were taken from 60 oral cancer patients and 10 controls. Blood 
samples were collected from all the human subjects. A thorough proper history with 
special emphasis on the areca nut & betel quid intake was taken. Patients having 
habit of smoking and/or alcohol intake were excluded from the present study. 
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Age Incidence 
In this study the highest number was between 50-75 years of age group i.e. 62 
individuals (62%) suffering from cancer. Peak age incidence in Wahi's series (1958) 
was 50-54 years while in another study by Sanlcararanayanan et ai, (1989), 45% of 
oral cancer cases were between 5"^  & 6"^  decade. In study by Chiang CP et al, 
(1999), 51.85% patients belonged to 50-70 age group. The maximum incidence, 
according to Kuo MY et al, (1999), is between 50-70 year age group (64.5%) while 
in another study by Huang et al, (2001), 60% of oral cancer cases were between 50-
70 year age group. 
There was no significant difference in age incidence between the age groups of 
patients of our series and that of other workers. 
The average age in this study was 56.75 years in patients in comparison to 54.8 
years in the study of A.Nandakumar et al, (1990) and 50.35 years in the study of 
D.N. Rao et al, (1994). The average age in study by Stefania Staibano et al, (1998) 
was 62.04 years while it was 50 years in study by Chang et al, (2002). 
Sex Incidence 
Oral cancer is more common in males as compared to females. Krihna et al, (1967) 
reported the incidence of males to be 77.6% while Mehrotra R. et al, (2003) from 
Motilal Medical College Allahabad have reported about 74% of oral cancer in 
males. In our series, also, males constituted about 15% of the total cases. 
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In Wahi's series (1958), the male female ratio was 2:1. In case control study by 
Krishna et al, (1967), there were 552 males and 224 females i.e. 2.5:1 ratio. In 
Mehrotra series, (2003), the female ratio was 2.3:1. In our series, it was 3:1. Mean 
age of male and female cases in our series was 58 and 53 years respectively while 
the mean age was found to be 63.5 years for males and 60.6 years for females in 
study by Langdon JD et al, (1977). 
Relation of tobacco and betel quid chewing with oral cancer 
In our study we have observed that tobacco and betel quid chewing is significantly 
associated with development of oral cancer. In India, association of tobacco and 
betel quid chewing and smoking with oral cancer has been demonstrated in earlier 
studies (Jayant et al, 1977, Motani, 1988; Shankaranarayanan et al, 1989; 
Nandakumar et al, 1990). The observations made by all of them pointed that the 
habit of tobacco and betel quid chewing is important risk factor in development of 
oral cancer. Our findings are in accordance with observation made by earlier 
studies. 
Habit of Paan chewing is common in India in both genders. Paan generally includes 
calcium hydroxide, areca nut (from the areca catechu tree) and betel leaf (from the 
piper betel vine). R. Sankaranarayanan et al, (1989) showed that paan-tobacco 
chewing is major risk factor for cancers of buccal and labial mucosa. Similarly 
Nandakumar et al, (1990) confirmed that paan tobacco chewing is a major risk 
factor in the occurrence of cancers of the oral cavity. In the study conducted by 
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Prabha Balaram et al, (2002), 591 oral cancer cases (309 males and 282 women) 
with 584 hospital controls were taken. They found that most cases of oral cancer in 
both genders were attributed to habit of paan tobacco intake. 
Incidence of site of lesion 
In our series, maximum 45 cases (45%) were of cheek carcinoma (Buccal mucosa) 
followed by malignancy of tongue (22%) and the floor of mouth (17%). 
In Wahi's series (1958), cases of carcinoma cheek were maximum in the oral cancer 
patients (53.91%). In a study conducted by Rao et al, (1994), the frequency of 
carcinoma cheek was maximum (44.4%). In study conducted by Agarwal et al, 
(1999), buccal mucosa was predominant site in betel related oral cancer. Ranasinghe 
et al, (1993) have also shown that buccal mucosa cancer is predominant site of oral 
cancer in tobacco and betel quid chewers while Chang et al, (2002) found 57.8% 
cases of oral cancer to be cheek carcinomas in betel and tobacco related oral cancer. 
Our findings about incidence of site of lesion are in accordance with earlier studies. 
p53 Expression 
The immunohistochemical detection of p53 in biopsy specimen as a potential marker is 
of immense interest to researchers, as it is most commonly identified mutated gene in 
various human cancers like lung, breast, prostrate and oral cancer. 
CHAPTER 5: DISCUSSION 100 
The gene coding for p53 protein i.e. TP53 is located on human chromosome 17 P 13:1 
and encodes a 53 KDa nuclear phosphoprotein that plays an important role in regulation 
of normal cell proliferation (Raybaud-Diogene et al, 1996;Lane and Benchimol, 1990). 
The wild type p53 protein has a half life time of 6-20 minutes (Chiang et al, 2000), while 
the mutant form has a half life of several hours and can be detected 
immunohistochemically. 
p53 mutations are often associated with the development and/or progression of malignant 
neoplasm (Allred et al, 1993). About 90% of mutation at p53 locus were found to be 
mis-sense mutations, within the region of exon 5 to 8 (Lane DP, 1998 and Lain et al, 
1999). Immunohistochemical studies of p53 expression in SCC of oral mucosa has shown 
overexpression of p53 protein (Kaur e/a/., 1994; Kuttan e/o/., 1995; Baral e/a/., 1998; 
Change/a/., 1999; Chiang e/a/., 1999; Pande er o/., 2002). 
In the present study, immunohistochemical studies for p53 expression was done on 
formalin fixed and paraffin embedded tissue sections, using FL-393 antibody (Santa Cruz 
Biotechnology) on biopsy specimens of 60 oral SCC patients with tobacco and betel quid 
chewing habit and 10 controls. Only strong brown nuclear staining was considered 
positive and p53 scoring was done in accordance to Hall and Lane (1994) and Chiang et 
al, (2000). The scores were expressed as the percentage of positive cases in each 
category and the percentage of p53 positivity in each case. 
In control specimens who were taken from normal individuals, there was no expression 
CHAPTER 5: DISCUSSION 101 
of p53 protein. This can be attributed to fact that p53 in its wild form has very short Hfe 
time (16-20 min) and can not be detected by immunohistochemistry. In present study, 
increased percentage of positive cases as well as mean p53 percent positivity was 
observed with increasing grade of differentiation in oral squamous cell carcinoma (oral 
SCC) patients with tobacco and betel quid chewing habit. Thirty nine oral SCC cases 
(65%) showed positive p53 expression and mean positivity was 26.46 + 23.90. 
Many previous studies have reported similar positivity in oral SCC patients with tobacco 
r32'i 
and betel quid chewing habit. Agarwal et al, (1999) reported that 65.3% — of cases 
of oral SCC with tobacco and betel quid chewing habit showed p53 positivity while 
( 69 ^  Pande et al, (2002) reported 65% positivity, Jie Xu et al, (1998) reported 59% 
— positivity and Kaur et al, (1998) reported 70% positivity respectively in 
patients with tobacco and betel quid chewing habit. However lower values were observed 
by Kuttan et al, (1995), Baral et al, (1998), Thongsukai et al, (2001) who reported 
^ 3 ^ 
U3, 
56.5% , ^22^ 
v48y 
45.8%, and 032^ 
V'56y 
38.5% positivity respectively but all researchers 
reported increase in number of positive cells. 
In our study, we further investigated the expression of p53 in various sites of oral cavity. 
p53 expression was more frequently seen in gingivia (-, 100%), floor of mouth 
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(-,71%), tongue (7/10, 70%) and buccal mucosa (— ,64.5%). There are only few 
studies which have correlated the expression of p53 with site of incidence in oral cavity. 
Kaur et al, (1998) found that there was no association between p53 expression and 
primary site of cancer (p=0.08). Similarly Claudia et al, (2006) found no association 
between p53 expression and different oral sites (p=0.53). In our study, expression of p53 
was not found to be associated with site of oral cancer (p=0.964) thus supporting the 
earlier studies that p53 expression is independent of site of incidence of oral cancer. 
The complete absence of p53 positivity in some squamous cell carcinomas was explained 
by Nylander et al, (2000), as the tumors completely lacking detectable p53 could either 
comprise of wild tumor protein or have a change in function in TP53 gene resulting in 
production of a truncated, non-functional and non detectable protein. 
The relationship between p53 expression and tumor grade was also evaluated in our 
study. An increased positivity with increasing grade was observed in the present study. 
The difference was found to be significant between well differentiated (20.0 ± 19.32) and 
poorly differentiated (47.5 ± 31.38) oral SCC, p=.001. However no statistical 
significance (p=0.27) was observed in p53 positivity among poorly differentiated 
SCC (p53 positivity = 47.5 ± 31.38) and moderately differentiated SCC (p53 
positivity = 29.33 ± 23.50), as well as between well differentiated SCC (p53 
positivity = 20 ± 19.32) and moderately differentiated SCC (p53 positivity = 29.33 
±23.50), p value =0.27. 
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Although most of the published data have shown no positive relationship between p53 
expression and histological grading of oral SCC (Chiang et al, 1999; Saranath et al, 
1999. Kerdpon et al, 2001). However, some studies have demonstrated a positive 
correlation between p53 expression and high grade of malignancy (Kaur et al, 1998). In 
our study, significant association was found between p53 positivity and degree of 
differentiation of tumors (p= .029). Similar to results in our study, Zariwala et al, (1994) 
and Shintani et al, (1995) found a tendency towards higher incidence of p53 positivity in 
poorly differentiated oral carcinomas. 
Cyclin Dl Expression 
Cyclin Dl gene encodes a protein that is a cell cycle regulator (Hunter et al, 1994). The 
Cyclin Dl gene (CCNDl, bcl-1 or PRADl) located on chromosome 1 Iq 13 (Jaun Carlos 
et al, 2002) encodes a protein that forms a complex with Cyclin dependent Kinases, 
CDK4 and CDK6. Cyclin D-CDK4 and CDK6 complexes phosphorylate Rb 
(Retinoblastoma) protein during the Gl-S transition which leads to their dissociation 
from the EF2 transcriptional factor and the initiation of DNA replication (Michalides 
RJAM et al, 1999; Kudo et al, 2000). Cyclin Dl overexpression, either by amplification 
or transcriptional upregulation, shows accerelated Gl progression and cell enters in the S 
phase, with lower cell dependence on growth factors for proliferation (Kuo MY et al, 
1999). 
Immunohistochemical studies of cyclin Dl expression in SCC of oral cavity has shown 
overexpression of cyclin Dl protein (Akerall JA et al, 1997; XU J et al, 1998; Lam KY 
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et al, 2000). In present study, immunohistochemical studies for cyclin Dl expression 
was done on formalin fixed and paraflTin embedded tissue sections, using H-295 antibody 
(Santa Cruz Biotechnology) on biopsy specimens of 60 oral SCC patients with tobacco 
and betel quid chewing habit and 10 controls. Only strong brown nuclear staining was 
considered positive and the scores were expressed as the percentage of positive cases in 
each category and the percentage of Cyclin Dl positivity in each case. 
In control specimens who were taken from normal individuals, there was no expression 
of Cyclin Dl protein. In present study, an increased percentage of positive cases as well 
as mean cyclin Dl positivity was observed in oral SCC patients with tobacco and betel 
quid chewing habit. Thirty five oral SCC (58.33%) cases showed positive Cyclin Dl 
expression and mean positivity was 22.16 ± 22.18. 
Many previous studies have reported similar positivity in oral SCC patients. Arora et al., 
(2004) reported that 61% of cases of betel related oral SCC showed Cyclin Dl positivity 
while Lam et al, (2000) reported 63% positivity. Similarly Staibano et al, (1998) 
reported 60% positivity and Gimenez-conti IB et al, (1996) reported 61% positivity for 
Cyclin Dl in oral SCC patients. Angadi et al, {imi), Akervell et al, (2002), Kuo et al, 
(1999) and Van Oijen et al, (1998) have observed higher cyclin Dl positivity in oral 
SCC patients and have reported 70.7%), 78%, 83% and 69% positivity respectively. 
However lower values were observed by koontongkaew et al, 2000, Takes et al, 
(1998); Xu J et al, (1998); Akervall et al, (1997), Michalides et al, (1995) who 
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reported 39.62%, 29%, 38%, 43% and 33% positivity respectively for Cyclin Dl in oral 
s e c patients. 
In our study, we further investigated the expression of Cyclin Dl expression in various 
sites of oral cavity. Cyclin Dl expression was more frequently expressed in hard palate, 
buccal mucosa and lip and less frequently in tongue and floor of mouth. There are only 
few studies that have described the expression of Cyclin Dl in various sites of oral cavity 
in oral SCC patients. Akervell et al, (1997) and Xu J et al, (1998) reported that 
expression of Cyclin Dl in oral SCC patients was more frequently seen in sites like 
tongue and retromolar region. In our study, Cyclin Dl expression was more frequently 
expressed in hard palate \ - ,75% 4 
21 •^  
, buccal mucosa | —,67% and lip 31 ) -,60% v5 J . The 
correlation between Cyclin Dl expression and primary site of oral cancer was also 
evaluated in our study. It was found that there was no significant association between 
Cyclin Dl expression and primary site of oral cancer (p=0.528). Similar results were 
reported by various studies (Kuo et al, 1999; Carlos et al, 2002) who found no 
association between Cyclin Dl expression and primary site of oral cancer. 
The relationship between Cyclin Dl expression and tumor grade was also evaluated in 
our study. An increased positivity with increasing grade was observed in the present 
study. The difference was found to be significant between well differentiated SCC 
(Cyclin Dl positivity=l6.61 ±17.89) and moderately differentiated SCC (Cyclin Dl 
positivity= 24.38+21.93, p=.002) as well as between well differentiated SCC 
(Cyclin Dl positivity= 16.61 +17.89) and poorly differentiated SCC (Cyclin Dl 
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positivity=37.0±32.51, p=.043). Similarly statistically significant difference was 
observed between moderately differentiated SCC (Cyclin Dl positivity= 
24.38±21.93) and poorly differentiated SCC (Cyclin Dl positivity=37.0±32.51, p 
=.043). Although most of published data have shown no positive relationship between 
Cyclin Dl expression and histological grade of oral SCC (Kuo MY et al, 1999; Wu M et 
al, 2002; Neves Adac et al, 2004) but Angadi et al, (2007) have observed positive 
correlation between Cyclin Dl expression and histological grade of oral SCC. In our 
study, we found no significant association between Cyclin Dl positivity and degree of 
differentiation of tumor (p=0.138) in oral cancer patients with tobacco and betel quid 
chewing habit. Further in our study, we found a tendency towards higher incidence of 
Cyclin Dl positivity with high grade of differentiation of tumors. Similar results were 
reported by Lam KY et al, (2000) who found that Cyclin Dl expression was more 
positive in high grade lesions. 
hOGGI Genotyping 
Molecular cloning of a human counterpart of yeast OGGI paved way for possible 
application of hOGGI variants as genetic markers for individual susceptibility to various 
cancers (Aburatani et al, 1997; Radicella et al, 1997). The hOGGI gene maps to 3p25 
chromosomal region and encodes a DNA glycosylase/AP-lyase that catalyzes removal of 
8-OH-dG adducts as part of the base excision repair pathway (Boiteux et al, 2000; 
Sunaga et al, 2001). 8-OH-dG is one of major forms of DNA adducts induced by 
oxidative damage and increased 8-OH-dG formation in DNA is likely to be involved in 
mutagenesis and carcinogenesis (Cheng et al, 1992; Kamiya et al, 1992). The hOGGI 
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gene is expressed as 12 alternatively spliced isoforms with only the la-form containing a 
nuclear localization signal (Shinmura et al, 2000) while P-hOGGl is targeted to 
mitochondria. Although no differences in catalytic activities were observed between the 
326 Cys and 326 Ser variants in one study (Dherin et al, 1999), the hOGGI protein 
encoded by wild type Ser326 allele exhibited substantially higher DNA repair activity 
than the 326Ser variant in an in vitro E.coli complementation activity assay (Kohno et al, 
1998). 
At least 10 polymorphism of hOGGI have been identified, one of which is C->G at bp 
(C1245G) in the la specific exon 7 that causes an amino acid substitution from Ser to 
Cys in codon 326 (Ser 326 Cys), potentially resulting in functional alteration (Kohno et 
al, 1998). In the present study, the association between Ser"^ Cys polymorphism and 
oral cancer risk was evaluated in tobacco and betel quid chewers. The study consisted of 
100 oral cancer patients with tobacco and betel quid chewing habit and 150 controls. In 
this study we have evaluated the risk of combined variant genotype (Ser/Cys+Cys/Cys) 
versus wild type homozygote (Ser/Ser) genotype to evaluate the association between 
Ser^ ^^ Cys polymorphism and oral cancer risk. 
The epidemiological studies that have evaluated the association between polymorphism 
at codon 326 of hOGGl and cancer risk have reported conflicting results. Elahi et al, 
(2002), Marchand et al, (2002), Xu et al, (2002), Cho et al, (2003) and Jiao et al, 
(2007) have reported that Ser^ ^^ Cys polymorphism is associated with risk of 
oropharyngeal and laryngeal, lung, prostrate, nasopharyngeal and gallbladder cancers 
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respectively. While Choi et al, (2003), Zhang et al, (2004), Monteiro et al, (2005), 
Poplawski et al, (2006) and Park et al, (2007) have reported that there is no association 
of ser^ ^^ Cys polymorphism with breast, head & neck, laryngeal, gastric and colorectal 
cancers respectively. 
Sugimura et al, (1999) have reported that there is no association of hOGGI Ser^ ^^ Cys 
polymorphism with lung cancer susceptibility when different types of lung cancer cases 
were taken together but hOGGI Ser^ ^^ Cys polymorphism is independently associated 
with increased risk of lung squamous cell carcinoma (OR=3.01, 95%C 1 = 1.33-6.83)and 
non-ademocarcinoma (OR=2.18,95%C 1=1.05-4.54). 
Kim et al, (2003) and Hashimoto et al, (2006) have reported that there is no association 
of Ser^ ^^ Cys hOGGI polymorphism with colon and head and neck carcinomas 
respectively but positive association is found between Ser^ ^^ Cys polymorphism in heavy 
smokers, in both colon (OR=2.75, 95% Cl=l.07-7.53) and head and neck (0R=8.1, 95% 
Cl=1.06-61.73) carcinomas. Similarly Takezaki et al, (2002) have reported that there is 
no association of Ser^ ^^Cys polymorphism with stomach cancer but the association is 
significant in alcohol drinkers. These findings suggest that hOGGI ser^ ^^ Cys 
polymorphism may alter the impact of some environmental factors on cancer 
development. In our study, we have observed that Ser^ ^^ Cys polymorphism is 
significantly (p=0.00)associated with oral cancer risk in tobacco and betel quid chewers. 
Most of the studies have reported that Ser^ ^^ Cys polymorphism increases the risk of 
cancer while one study has reported decrease in cancer risk. Increase in lung cancer risk 
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due to hOGGI ser^ ^^Cys polymorphism has been reported by Wikman et al, (2000) 
[OR=2.2, 95% Cl=0.4-11.8] and Le Marchand et al, (2002) [0R=2.1, 95% CI = 1.2-3.7] 
respectively. Similarly Cho et al., (2003), Chen et al, (2003) and Xing et al, (2001) 
have reported increase in nasopharyngeal [OR=3.0, 95% Cl = l.0-8.8], prostrate cancer 
[0R=2.1, 95% Cl=1.2-3.8] and esophageal cancer[0R=1.9, 95% Cl=1.3-2.6] 
respectively. But Hansen et al, (2005) have reported that hOGGl ser^ ^^ Cys 
polymorphism is associated with lower risk of colorectal cancer (OR=0.56, 95% 
Cl=0.33-0.95). In our study, we observed that hOGGl Ser '^^ Cys polymorphism 
increases the risk of oral cancer in tobacco and betel quid chewers of northern India 
(OR=2.3, 95% Cl= 1.5-3.61). Thus in our study we have observed positive correlation 
between Ser^ ^^ Cys polymorphism and oral cancer risk. We have found that Ser^ ^^ Cys 
polymorphisms lowers DNA repair ability in tobacco and betel quid chewers which 
results in increase in risk of oral cancer in this epidemiologically distinct population. 
XRCCI Genotyping 
Human cancer can be initiated by DNA damage caused by ultraviolet rays, ionizing 
radiation and environmental chemical agents. To safeguard the integrity of genome, 
humans have developed a set of complex DNA repair systems. Among the five main 
DNA maintenance mechanisms operating in mammals, base excision repair is the 
primary guardian against damage where non bulky base adducts produced by 
methylation, oxidation, reduction or fragmentation of bases by ionizing reduction or 
oxidative damage are removed (Yu et al, 1999). Therefore base excision repair is a 
universal event in the cells and is relevant for preventing mutagenesis. 
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XRCCI, one of more than 20 genes that participate in base excision repair pathway 
encodes a scaffolding protein that functions in the repair of single strand breaks, the most 
common lesion in cellular DNA (Caldecott et al, 1995). Both biological and biochemical 
evidence indicate a direct role for XRCCI in base excision repair because it interacts with 
complex of DNA repair proteins, including poly (ADP-ribose) polymerase DNA ligase 
III, and DNA polymerase P . 
Mouse XRCCI -1- Knockout mutation is lethal and mutation in XRCCI results in an 
increased sensitivity to these agents and decreased genetic stability, including increased 
frequencies of spontaneously or induced chromosome translocations or deletions 
(Thompson et al, 2000). There are a total of eight non synonymous coding single 
nucleotide polymorphism in XRCCI, three of which are common and lead to amino acid 
substitutions in XRCCI at codon 194 (Exon 6, base C to T, amino acid Arg to Trp), 
codon 280 (Exon 9, base G to A, amino acid Arg to His) and codon 399 (Exon 10, base G 
to A, amino acid Arg to Gln).These three polymorphism occur at residues that are 
identical in humans, hamster and mouse suggesting that these amino acid are 
evolutionary conserved (Shen et al, 1998; Lamerdin et al, 1995). Arg 399 Gin 
polymorphism is located in the region of BRCT-1 interaction domain of XRCCI within a 
poly (ADP-ribose) polymerase binding region and has been extensively studied as 399 
Gin variant allelic is most frequently found. XRCCI Arg'^ '*Trp and Arg^^^His variants 
occur in the newly identified proliferating cell nuclear antigen binding region (Fan et al, 
2004). 
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There are relatively few studies conducted to examine the association between Arg^ '^^ His 
variant and cancer risk and only one study evaluated the association of Arg His 
polymorphism and altered DNA adducts (Zhibin HU et al, 2005). In the present study 
the association between Arg^^ ^His polymorphism and oral cancer risk in tobacco and 
betel quid chewers was evaluated. The study consisted of 100 oral cancer patients with 
tobacco and betel quid chewing habit and 150 controls. Because of the rare variant allelle 
frequencies of Arg^*°His polymorphism, we evaluated only the risk of combined variant 
genotypes (His/His+Arg/His) versus wild type homozygote (Arg/Arg). 
The epidemiological studies that have evaluated the association between polymorphism 
at codon 280 of XRCCI and cancer risk have reported conflicting results. Ratnasingha et 
al, (2001), Carla et al, (2002), Moullan et al, (2003),Cho et al, (2003), and Hao et al, 
(2004) have shown that Arg^^ ^His polymorphism is associated with risk of 
lung,prostrate,breast, nasopharyngeal, and esophageal cancers respectively. Other studies 
have shown that there is no association of Arg^*°His polymorphism with risk of oral 
cancer (Ramachandran et al, 2006; Majumder et al, 2007) breast cancer (Metsola et al, 
2005), lung cancer (Mishra et al, 2003; Scheneider et al, 2005) and esophageal cancer 
(Lee et al, 2001) respectively. In a meta-analysis of 38 case control studies about 
association of XRCCI polymorphisms with cancer risk, Hu et al, (2005) observed that 
Arg^ *^^ His polymorphism is associated with cancer risk and individuals with the variant 
genotypes (His/His+His/Arg) had a borderline significantly increased cancer risk, 
compared with the individuals with wild type genotype (OR=I.19;95% CI=1.00-1.42). In 
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our study, we have observed that XRCCl Arg^*°His polymorphism is associated with 
oral cancer risk in tobacco and betel quid chewers (p=.015). 
Whether the Arg^*°His polymorphism increases or decreases the cancer risk, there are 
conflicting results. Some studies have reported that Arg^ **^ His polymorphism increases 
the risk of cancer while others studies have reported negative association between 
Arg^ °^His polymorphism and cancer risk. Ratnasingha et al, (2001) have observed that 
XRCCI Arg'^ '^^ His polymorphism increases the risk of lung cancer (0R=1.8, 95% 
C 1=1.0-3.4) while MouUan et al, (2003) reported that XRCCI Arg^*°His polymorphism 
increases the risk of breast cancer (0R=1.8, 95% Cl=l.07-3.05). Similar increase in 
prostrate cancer risk was observed by Carla et al, 2002 (0R=1.5, 95% Cl=0.7-3.5). But 
Cho et al, (2003) have reported that Arg^*°His polymorphism decreases the risk of 
nasopharyngeal cancer (OR=0.64, 95% CI =0.43-0.96). Similarly Hao et al, (2004) have 
reported that Arg^*°His polymorphism decreases the risk of esophageal squamous cell 
carcinoma (OR=0.79, 95% C 1=0.56-1.11). In our study, we observed that Arg^^ ^His 
polymorphism increases the risk of oral cancer in tobacco and betel quid chewers of 
northern India (OR=1.63, 95% Cl= 1.1-2.413). Thus in our study we have observed 
positive correlation between Arg^ ^^ His polymorphism and oral cancer risk. We have 
found that Arg^^^His polymorphism may result in lower DNA repair ability which results 
in increase in oral cancer risk in tobacco and betel quid chewers. 
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CYP2E1 Genotyping 
Both genetic and environmental factors are involved in the development of cancer. The 
environment-gene interaction on carcinogenesis has been well demonstrated by phase-1 
&. phase -II enzymes that are involved in the metabolism of carcinogens. An individual 
difference in the susceptibility to chemical carcinogens is one of the most important 
factors in the estimate of risk of cancer. Most chemical carcinogens require metabolic 
activation by phase 1 enzymes (cytochrome p-450) and detoxification by conjugation via 
the various phase 11 enzymes (epoxide hydrolase, N-actyl transferese etc.) Thus, the 
coordinate expression and regulation of phase I and phase II drug metabolizing enzymes 
and their metabolic balance may be an important host factor in determining whether 
exposure to carcinogens results in cancer or not. The phase I enzymes, CYP, activate 
many environmental procarcinogens by adding or exposing their functional 
groups(Kawajiri e/o/., 1991) 
CYP2E1 is ethanol induced phase 1 enzyme which has received much attention because 
of potentially important toxicological roles of this enzyme. Human CYP2E1 gene is 
highly conserved compared with other human p450 genes with products active in 
metabolism of xenobiotics. This enzyme is localized mainly in the liver but is also 
expressed and induced in the brain after ethanol treatment or ischemia and is also 
expressed at significant levels in human esophagus and other extrahepatic tissues 
(Nakajima et al, 1996; Lechevrel et a/., 1999). 
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The physiological role of this enzyme seems to be connected mainly with the conversion 
of acetone to gluconeogenetic precursors. Among more than 70 different substrates 
specifically metabolized by this enzyme are most of the organic solvents, drugs 
(paracetomol, chlorzoxazone) and are several potential carcinogens (nitrosamines, 
benzene, aniline) which are transferred to their active forms. In addition, CYP2E1 causes 
oxidative stress and the oxygen radicals generated by this enzyme are able to initate 
NADPH- dependent lipid peroxidation with the concomitant production of cytotoxic 
aldehydes (Hu et al, 1997). Although certain chemicals and physiological status can 
induce the activity of CYP2E1, considerable inter-individual variation has been observed 
before and after induction, suggesting that the variation may be determined by genetic 
factors in the locus. Thus any functional polymorphism of this enzyme might be an 
important factor in determining the relative risk of alcohol mediated hepatotoxicity, any 
form of cancer or susceptibility for drug toxicity. 
Human CYP2E1 gene is polymorphic at several sites, the most important being PstI site, 
Rsal site and Dral site. Pstl and RSal site are present in the 5' flanking region while 
Dral site is present in intron 6. Phenotypic studies using the drug chlorzoxazone as a 
metabolic probe have shown that individuals with the variant Rsal allele have a lower 
CYP2E1 activity and that enzyme activity is less inducible by ethanol (Lucas et al, 
1995). A polymorphism of CYP2E1 detected by Rsal restriction enzyme may be 
functionally important because it is located in a putative binding site for the 
transcriptional factor HNF 1 and has been associated with higher levels of CYP2E1 
transcription (London etal, 1996). 
^•BiaaBiaBBs^gaa^HBa^aBiaBB^BBaii^aaai^BB^BaBBaaaasBai 
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In the present study, the association of Rsal polymorphism and Dral polymorphisms of 
the CYP2E1 gene with oral cancer risk in tobacco and betel quid chewers was evaluated. 
The study consisted of 100 oral cancer patients with tobacco and betel quid chewing habit 
and 150 controls. To find any association between these CYP2E1 Polymorphisms and 
oral cancer risk, we evaluated the risk of combined variant genotypes 
(AC D C ^ 
\— +—for Rsa\,— +—for Dral versus wild type homozygote 
\C C C C J 
f A D \ 
—for Rsal,—for Dral genotypes. 
Rsal polymorphism present in the 5' flanking region of CYP2E1 is most extensively 
studied polymorphism of CYP2EI but the studies that have evaluated association of Rsal 
polymorphism of CYP2E1 and cancer risk have reported conflicting results. Hildesheim 
et ai, (1995), Ladero et al, (1996), Marchand et al, (1998), Tan et al, (2000) and 
Sugimura et al, (2006) have reported that CYP2E1 Rsal polymorphism is associated 
with nasopharyngeal, liver, lung, esophageal and oral carcinomas respectively while 
Matthias et al, (1998), Watanabe et al, (1995), Ferreira et al, (2003), and Choi et al, 
(2003) have observed that there is no association of Rsal polymorphism with head and 
neck, lung, prostrate and breast carcinomas respectively. Choi et al, ( 2003) have 
reported that although there is no association between breast cancer risk and Rsal 
polymorphism but increased cancer risk is found in ever drinking women (OR=1.9, 95%, 
Cl= 0.99-3.83) with CI C2 or C2 C2 genotype compared to non-drinkers with CYP2E1 
CI/CI genotype. 
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Similarly Bouchardy et al., (2000) have reported that Rsal polymorphism is associated 
with risk of head and neck carcinoma (0R= 2.0, 95% Cl= 1.0-3.5) but the risk is 
increased in drinkers (OR=5.8, 95% Cl= 1.9-18.2). These findings suggest that gene-
environment interactions play an important role in oral cancer. In our study, we have 
observed that CYP2E1 Rsal polymorphism is significantly (p=.001) associated with risk 
of oral cancer in tobacco and betel quid chewers. 
Most of studies that have investigated association of Rsal polymorphism with cancer risk 
have observed increase in the risk of cancer while one study has reported decrease in 
cancer risk. Hildesheim et al., (1995) reported that individuals who have C2/C2 genotype 
were at increased risk for nasopharyngeal carcinoma (0R= 7.7, 95% Cl= 0.87-6.8) 
compared to those who had Ci/Ci genotype while Bouchardy et al., (2000) reported that 
subjects with C1C2 or C2C2 genotype have increased risk of oral cavity / pharyngeal 
cancer (0R= 2.6, 95% Cl= 1.0-6.6) but Marchand et al., (1998) reported that Rsal 
homozygous variant genotype (C2/C2) was associated with 10 fold (0R= 0.1, 95% Cl= 
0.0-0.5) decrease in risk of overall lung cancer. We observed positive correlation between 
CYP2E1 Rsal polymorphism and oral cancer risk. Our findings support the hypothesis 
that environmental exposure to the carcinogens plays an important role in the etiology of 
oral cancer. In our study, we observed that Rsal polymorphism of CYP2E1 gene 
increases the risk of oral cancer in tobacco and betel quid chewers. The carriers of C 
variant allele (A/C or C/C) were at increased risk of oral cancer (OR=2.0, 95%C 1=1.3-
2.9). 
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The epidemiological studies that have evaluated the association of CYP2E1 Dral 
polymorphism with cancer risk have reported results which are inconclusive. Some 
studies have reported the association of CYP2E1 Dral polymorphism with cancer risk, 
while other studies have found no association. Hildesheim et al, (1995) Ferreira et al, 
(2003) and Sugimura et al, (2006) have reported that CYP2E1 Dral site polymorphism 
is associated with risk of nasopharyngeal, prostrate and oral cancers respectively. While 
Kato et al, (1994) and Matthias et al, (1998) have reported that there is no association of 
Dral polymorphism with lung and head and neck carcinomas respectively. Bouchardy et 
al, (2000) have further reported that risk of oropharyngeal cancer was increased in 
individuals with CC or CD variant genotypes as compared to other individuals (0R= 
2.0, 95% Cl= 1.0-3.9) but the risk was more increased in drinkers (0R= 5.8, Cl= 1.0-
3.5) suggesting that gene-environment interactions play a significant role in oral cancer. 
In our study, we have observed that CYP2E1 Dral polymorphism is significantly 
(p=.049) associated with risk of oral cancer in tobacco and betel quid chewers. 
Most of earlier investigations that have reported association of CYP2E1 Dral 
polymorphism with cancer risk have observed increase in the risk of cancer while some 
studies have reported decrease in cancer risk. Hildesheim et al, (1995 ) have reported 
that subjects with CC variant genotypes were at increased risk of nasopharyngeal 
carcinoma (0R= 5.0, 95% Cl= 0.95-1.6) while Ferreira et al, (2003) have reported that 
CYP2E1 Dral polymorphism is associated with increased risk of prostrate cancer (0R= 
2.12, 95% Cl= 1.11-4.05). However, Marchand et al, (1998) have reported that CC 
homozygous variant Dral genotypes was associated with 5 fold decrease in overall lung 
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cancer (0R= 0.2, 95% Cl= 0.1-0.7) compared to corresponding homozygous wild type. 
In our study, we observed that Dral site polymorphism of CYP2E1 gene increases the 
risk of oral cancer in tobacco and betel quid chewers. The carriers of C variant allele (CC 
or CD) were at increased risk of oral cancer (OR=1.37; 95% CI =0.9-1.89). Thus in our 
study, we have observed positive correlation between CYP2E1 Dral polymorphism and 
oral cancer risk. 
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CHAPTER 6 SUMMARY AND CONCLUSIONS 
The present study was conducted in the Department of Biochemistry, Jawaharlal 
Nehru Medical College, AMU, Aligarh during the period November, 2004 to March 
2007. The study comprised of patients of oral cancer attending the 
Otorhinolaryngology (E.N.T) O.P.D. or outdoors admitted to their wards. The salient 
features of the present study are as foilows:-
The present study comprised of 100 oral cancer patients and 150 control subjects. 
Biopsy specimens were taken from 60 oral cancer patients and 10 controls. 
Blood samples were collected from all the subjects. 
The purpose of the present study was to evaluate the expression of p53 and Cyclin Dl 
in tobacco and betel quid chewers of northern India. We further aimed to evaluate the 
association of hOGGl Ser^ ^^Cys, XRCCI Arg^^^His, CYP2E1 Oral and CYP2E1 Rsal 
polymorphisms with risk of oral cancer in tobacco and betel quid chewers. 
The 60 oral cancer biopsy samples were further divided into well differentiated, 
moderately differentiated and poorly differentiated squamous cell carcinomas on basis 
of degree of differentiation. Well differentiated SCC was found to be the commonest, 
34 cases (56.66%) followed by moderately differentiated SCC, 18 cases (30%) and 
poorly differentiated SCC, 08 cases (13.33%). 
• The cases belonged to age group of 25-100 years while the controls belonged 
to age group of 0-100 years. 
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There were 75 males (75%) and 25 females (25%) in the cases while 115 
males (76.66%) and 35 females (23.33%) in the controls. 
• The mean age of male and female patients was 58 and 53 years respectively 
while mean age of male and female controls was 56 & 54 years respectively. 
• 
• 
There was definite male preponderance with a male to female ratio of 3: 1 in 
cases and 3.28:1 in controls. 
Most cases (68.97%) presented with some complaint within first 6 months 
of the start of the lesion. 
• Maximum number of patients complained of dysphagia (80 cases) 
followed by pain in the lesion (50 cases), burning in the mouth & throat 
(45 cases) and pain during swallowing (29 cases). 
• Tobacco and betel quid chewing was found to be very important risk factor for 
development of oral cancer by chi square test(x^ ~ 135.226, p=0.00). 
• Maximum cases ,45 (45%) were having malignancy of buccal mucosa 
,followed by tongue, 22 cases (22%) and floor of mouth ,17 cases (17%) 
respectively. Other malignancies were less common like lip (6%), hard palate 
(5%) and gingivia 3(%). 
• Histopathology revealed squamous cell carcinomas in all oral cancer biopsy 
specimens. 
Protein Expression 
Sixty biopsies of oral cancer patients with tobacco and betel quid chewing habit and 
10 normal biopsies were immunohistochemically evaluated for p53 and cyclin Dl 
expression and the results were expressed as positive cases (%) and positivity. 
p53 Expression 
• p53 immunostaining was positive in 39 (65%) cases of oral cancer with a p53 
positivity of 26.46±23.90 (mean+SD) while there was no detectable p53 
expression in controls. 
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• The percentage of positive cases as well as p53 positivity showed an increase 
as the grade of differentiation advanced. Significant association was found 
between p53 positivity and degree of differentiation of tumors (p=.029). 
• A significant difference in p53 positivity W£is noted on comparing well 
differentiated (20.0, ± 19.32) and poorly differentiated (47.5, ± 31.38) OSCC, 
p=.001. 
p53 expression was more frequently seen in gingivia (100%), floor of mouth 
(71%), tongue (70%) and buccal mucosa (64.5% ) and less in sites like hard 
palate (50%) and retro molar region (50%). 
There was no association between p53 expression and primary site of cancer 
(p=0.964) in tobacco and betel quid chewers from northern India. 
Cyclin Dl Expression: 
• Cyclin Dl immunostaining was positive in 35 cases of oral cancer with a 
Cyclin Dl positivity of 22.16±22.18 (mean ± SD) while there was no 
detectable Cyclin Dl expression in controls. 
• The percentage of positive cases as well as Cyclin Dl positivity showed an 
increase as the grade of differentiation advanced. 
• No Significant association was found between Cyclin Dl positivity and degree 
of differentiation of tumors (p=0.138). 
• A significant difference in Cyclin Dl positivity was observed (p=.043) on 
comparing well differentiated (16.61 ±17.89) and poorly differentiated 
(37.0±32.51) OSCC, as well as between well differentiated (16.61 ±17.89) 
and moderately differentiate OSCC (24.38±21.93 ), p= .002 .Similarly 
significant difference in Cyclin Dl positivity was observed on comparing 
moderately differentiated (24.38±21.93) and poorly differentiated 
(37.0±32.51) OSCC, p =.043. 
• Cyclin Dl expression was more frequently seen in hard palate (75%), buccal 
mucosa (67%) and lip (60%) while expression of Cyclin Dl was less in sites 
like gingiva (0%), tongue (40%) and floor of mouth (43%). 
• There was no association between Cyclin Dl expression and primary site of 
oral cancer (p=0.528) in tobacco and betel quid chewers of northern India. 
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Genetic Susceptibility 
One hundred blood samples of oral cancer patients with tobacco and betel quid 
chewing habit and 150 controls were evaluated by PCR-RFLP to study association of 
XRCCI Arg^^^His, hOGGI Ser^ ^^Cys, CYP2E1 Oral and CYP2E1 Rsal 
polymorphisms with oral cancer risk. 
XRCCI Arg"'"His polymorphism 
• XRCCI Arg^*°His Polymorphism was found to be associated significantly 
with risk of oral cancer in tobacco and betel quid chewers (p=.015). 
• The individuals with variant genotypes (Arg/His, His/His) were at increased 
risk of oral cancer (0R= 1.63, 95% CI=1.1—2.413) as compared to 
individuals having wild type homozygous genotype (Arg/Arg). 
hOGGI Ser326Cys polymorphism 
• hOGGI Ser^ ^^Cys polymorphism was found to be significantly associated with 
the risk of oral cancer in tobacco and betel quid chewers (p=0.00). 
• The individuals with the variant genotype (Ser/Cys or Cys/Cys) were at 
increased risk of oral cancer as compared to individuals having wild type 
genotype Ser/Ser (0R= 2.3, 95%C1= 1.5-3.61). 
CYP2E1 Rsal Polymorphism 
• 
CYP2E1 Rsal polymorphism was found to be significantly associated with the 
risk of oral cancer in tobacco and betel quid chewers (p=.001). 
• The individuals with the variant genotype (C/C or A/C) were at increased risk 
of oral cancer as compared to individuals having wild type genotype A/A 
(0R= 2.0, 95% Cl= 1.3-2.9). 
CHAPTER 6: SUMMARY & CONCLUSIONS 123 
CYP2E1 Dral Polymorphism 
• CYP2E1 Dral polymorphism was found to be significantly associated with the 
risk of oral cancer in tobacco and betel quid chewers (p=0.049) 
• The individuals with the variant genotype (D/C or C/C) were at increased risk 
of oral cancer as compared to individuals having wild type genotype D/D 
(0R= 1.37, 95% C1 = 0.9-1.89). 
Thus XRCCI Arg^*°His, hOGGI Ser^ ^^Cys, CYP2E1 Rsal and CYP2E1 Dral 
polymorphisms were associated with increased risk of oral cancer in tobacco and betel 
quid chewers in northern India. 
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